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ABSTRACT 
Evan L. Busch: Markers of Epithelial-Mesenchymal Transition and Colorectal Cancer Mortality: 
Time-to-Event and Latent-Class Analyses                                                                              
(Under the direction of Robert S. Sandler) 
 
 Most cancer arises in epithelial cells and most cancer deaths are due to metastases.  Many 
cancer patients diagnosed with local disease according to lymph-node evaluation and radiologic 
imaging later experience disease recurrence within a few years of surgery. An additional measure 
of cancer cell detachment from the primary tumor taken in the primary tumor itself at the time of 
surgery might improve our ability to identify which patients are at risk for recurrence and 
therefore should have their treatments adjusted accordingly. 
 Epithelial-mesenchymal transition (EMT) is a mechanism of cancer cell metastasis that 
connects epithelial cells to metastasis.  It identifies candidate markers for the additional 
diagnostic test needed to stratify cancer patients by risk for recurrence. 
 I measured the EMT markers E-cadherin, Integrin beta-6, and Snail in primary tumors 
from subjects in a population-based, case-only prospective cohort of colorectal cancer patients.  
Using Cox proportional hazards models, I estimated the association between each marker and 
time from surgery to death.  I found that E-cadherin expression measured as a weighted average 
of tumor cores was associated with time to death.  No other marker expression variable was 
associated with outcomes. 
 Using latent class analysis, I estimated the sensitivity and specificity of E-cadherin 
expression as a weighted average of tumor cores to classify subjects as those likely to have 
cancer cells detaching or not detaching from the primary tumor at the time of surgery, in 
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conjunction with lymph node evaluation and radiologic imaging.  Latent class analysis permitted 
estimation of sensitivity and specificity under the realistic assumption that none of the tests 
constituted a gold-standard measure of whether cancer cells had detached from the primary 
tumor by the time of diagnosis.  Across the various latent class models that I explored, I found a 
peak E-cadherin sensitivity of 59% and peak specificity of 94%. 
 My results suggested that E-cadherin measurements in colorectal primary tumors at the 
time of surgery might improve the ability of clinicians to assess whether the patient is at risk for 
recurrence.  Incorporating such measurements into standard colorectal cancer diagnostic 
procedures could thereby help to improve patient outcomes.  
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CHAPTER 1. SPECIFIC AIMS 
 Roughly 80% of cancer arises from epithelial cells and about 90% of cancer deaths are 
due to metastases (1).  Epithelial-mesenchymal transition (EMT) is a mechanism of cancer cell 
metastasis that links epithelial biology to the detachment of cancer cells from primary tumors 
(2).  EMT markers measured in primary tumor cancer cells could be important to identify 
patients at risk for metastatic disease, even among those with no evidence of metastatic disease 
according to lymph node evaluation or radiologic imaging.  The impact of EMT markers could 
be especially great in colorectal cancer (CRC), which is 95% epithelial in origin (3) and in which 
about 25% of patients diagnosed with local disease eventually experience recurrence (4).  This 
suggests that many patients have metastatic disease at the time of diagnosis that is not 
successfully captured by conventional diagnostics of lymph node evaluation and imaging. 
 Although several dozen studies of EMT markers in CRC primary tumors and patient 
outcomes have been conducted over the past decade, the methods and results have been 
inconsistent (5).  In addition, data analyses have been crude and not informative in terms of 
whether the markers could be translated to the clinic, where they could impact public health by 
modifying tumor stage diagnosis procedures.  I undertook this research to develop marker 
measurement and data analysis procedures for studies of EMT markers and patient outcomes that 
can standardize methods across studies and provide information that permits clear evaluation of 
whether and how a marker could be used clinically.  The goal was to develop methods that will 
facilitate translation of EMT markers to clinical use so that cancer patients may benefit from the 
opportunity that our biological knowledge of EMT has presented.  The procedures we developed 
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for this research were applied to subjects from a population-based, case-only prospective cohort 
of CRC patients.  The specific aims of the project were as follows: 
 Specific Aim 1: Estimate associations between EMT marker expression levels in 
CRC primary tumor cancer cells and time from surgery to patient death. 
 a) Identify the optimal scale on which to measure each marker. 
 b) Determine the set of adjustment covariates to include in statistical models to produce 
valid estimates of associations between EMT marker expression levels and patient outcomes. 
 c) Develop a method to identify clinically-informative cut points for observed values 
along the scale of expression chosen for a given marker. 
 Hypothesis: Low E-cadherin expression, and high Integrin beta-6 and Snail expression, 
will be associated with shorter times from surgery to death. 
Specific Aim 2: Using latent class analysis, estimate the sensitivity and specificity of 
EMT markers to assess cancer cell detachment from primary tumors without assuming 
that lymph node evaluation or radiologic imaging are gold standard measures of such 
detachment. 
 a) Conduct sensitivity analyses to evaluate how varying one’s assumptions about the 
sensitivity and specificity of lymph node evaluation and imaging impact estimates of the 
sensitivity and specificity of EMT markers. 
 b) Assess how varying the cut point used to determine dichotomous EMT marker 
expression status impacts estimates of the sensitivity and specificity of the EMT marker. 
 Hypothesis: EMT marker expression levels associated with time from surgery to death 
will have high sensitivity and specificity to assess cancer cell detachment from primary tumors. 
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CHAPTER 2. BACKGROUND AND SYSTEMATIC LITERATURE REVIEW 
 2.1. Colorectal cancer 
 Colorectal cancer (CRC) is a leading cause of morbidity and mortality both nationally 
and globally.  In the United States alone there are over 140,000 new cases and 50,000 deaths per 
year attributable to the disease, giving CRC the fourth-largest incidence nationally of any tumor 
site (after prostate, breast, and lung cancer) and second-largest mortality (after lung cancer) (6).  
As is typical of cancer generally, a patient’s prospects for a full recovery decline sharply the 
greater the spread of the tumor.  The five-year relative survival proportion is approximately 90% 
for localized tumors, 69% for tumors that have spread to adjacent lymph nodes and organs, and 
12% for tumors that have spread to distant organs at the time of diagnosis (7). 
 Despite substantial morbidity and mortality due to CRC, the United States has seen a 
declining disease burden.  Overall age-adjusted CRC incidence has fallen from a peak of about 
68 cases per 100,000 people per year in the mid-1980s to around 42 cases per 100,000 people per 
year in 2009 (8).  Similarly, overall age-adjusted CRC mortality has decreased from about 28 
deaths per 100,000 people per year in 1978 to roughly 16 deaths per 100,000 people per year in 
2009 (8).  The improved mortality rate has been attributed to a combination of screening via 
techniques such as colonoscopy; successful treatment via surgery, chemotherapy, and radiation 
therapy; and changes in population risk factor exposures (9, 10).  However, the fact that the CRC 
morbidity and mortality burden remains high despite these trends suggests that additional clinical 
innovations will be needed to drive the overall disease burden still lower. 
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 A number of risk factors are associated with CRC.  Increasing risk is associated with 
increasing age, as over 90% of cases are diagnosed in people over the age of 50 (10).  Smoking, 
diets high in fat and low in folate, and a history of colonic inflammatory disease also increase the 
risk of developing CRC (10).  Blacks are at higher risk for CRC with an age-adjusted incidence 
of nearly 53 cases per 100,000 people per year in 2009 compared to 41 cases per 100,000 people 
per year among whites (8).  Men are more likely to develop CRC with an age-adjusted incidence 
of about 48 cases per 100,000 people per year in 2009 versus 38 cases per 100,000 people per 
year among women (8). 
 Despite the vast increase in our biological understanding of cancer since the 1970s, our 
ability to capitalize on this knowledge to reduce cancer incidence and mortality has been 
relatively disappointing.  Many of the anti-tumor treatments in clinical use were developed 
decades ago without the benefit of the molecular and genetic insights obtained since (1).  
However, the failure to date to match expectations does not mean that the biological insights of 
recent decades do not open up rich possibilities for new clinical interventions that can improve 
CRC outcomes.  Translational research, which attempts to use basic biology knowledge to 
discover effective clinical interventions, holds tremendous promise to build on past advances in 
reducing CRC mortality. 
 2.2. Role of metastasis in CRC outcomes 
 To reduce the CRC mortality burden, effective interventions will target the ways in which 
CRC kills people.  Of course, one approach is to prevent the disease from occurring altogether, 
as polypectomy during colonoscopy often does.  When a tumor has already formed, an 
appropriate approach is to target the particular mechanisms that the tumor uses that ultimately 
lead to the patient’s death.  In CRC, as well as other cancers, this means controlling metastases. 
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 The capacity to invade and metastasize is widely recognized as a distinguishing 
characteristic of cancer, where metastasis can be defined as the spread of cancer cells to parts of 
the body distant from the primary tumor (11).  Such roving cancer cells are dangerous because 
they can found new tumors throughout the body.  More importantly, metastases are responsible 
for approximately 90% of deaths due to cancer (1); it is surprisingly rare for the primary tumor to 
directly kill the patient.   
 Therefore, when any patient is diagnosed with cancer, two of the most critical questions 
that must be answered are whether cancer cells have already begun to detach from the primary 
tumor and, if so, whether healthcare providers can still successfully treat the illness.  Our ability 
to answer these questions correctly depends on how accurately we can assess a host of additional 
factors.  One important issue is determining whether any cancer cells in the primary tumor 
appear to have been capable of breaking off from it.  A second consideration is whether 
metastases can be detected elsewhere in the body.  The latter is particularly difficult to determine 
because most metastases break away from the primary tumor as micrometastases, defined as “[a] 
metastasis that is composed of a single cell or a small clump of cells and is only apparent through 
microscopy” (1). This definition suggests that there may be limits to how well radiologic 
imaging can detect every metastasis that may exist in a patient’s body at the time of tumor 
removal surgery.  Micrometastases that break off from the primary just before the latter is 
removed would be too small to be seen by imaging at that time. 
 Determining whether cancer cells in the primary tumor at the time of surgery have 
acquired the ability to break off could suggest, by inference, whether other cancer cells might 
have already broken off.  This is an appealing approach to cancer treatment.  First, the primary 
tumor is relatively easy to locate.  Second, molecular assessment of whether the primary tumor 
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has been producing cells capable of detaching may add crucial information beyond traditional 
prognostic factors such as tumor size or grade, which can be limited in their ability to predict 
CRC outcomes (12, 13).  For example, while metastases are commonly thought of as being 
produced by large tumors, it has been shown that cancer cells can detach from small tumors (12).  
In short, whether a tumor has cancer cells detaching from it may be independent of its size, 
extent of locoregional spread, and therefore stage (except in the sense that any finding of distant 
metastases is by definition Stage IV).  A tumor that appears to be Stage I or II may be generating 
undetected micrometastases.  Thus, fully assessing the primary tumor after removal may require 
more measurements than the current diagnostics of lymph node evaluation and imaging. 
 2.3. Epithelial-Mesenchymal Transition 
 Given the importance of ascertaining whether a patient has metastatic disease, and the 
appeal of doing so in part in the primary tumor itself, what measurements of cancer cell ability to 
detach should be taken in the primary tumor?  Basic research in recent decades suggests that an 
important mechanism of cancer invasion and metastasis is epithelial-mesenchymal transition 
(EMT).  In EMT, epithelial cancer cells shed their epithelial characteristics and acquire a 
mesenchymal phenotype, which confers greater cell motility and ability to migrate out of the 
tissue of origin (2, 14).  EMT could potentially play an enormous role in CRC metastasis because 
roughly 95% of CRC tumors are adenocarcinomas, which arise from epithelial cells (3).  Indeed, 
about 80% of all cancer originates in epithelial cells (1).  It has been suggested that patients 
develop metastatic disease after cancer cells in the primary tumor acquire the capacity to undergo 
EMT (2).  Figure 1 illustrates the process: 
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Figure 1. Epithelial-mesenchymal transition and associated molecular markers (from Kalluri and 
Weinberg, 2009) (2) 
 
 
 
 Figure 1 shows that a large number of molecular markers have been associated with 
EMT, and the lists are not exhaustive.  This makes sense given that the model posits a global 
change in phenotype from one cell type to another.  Therefore, expression levels of many 
markers should change as part of the process.  Conceptually, EMT markers can be placed into 
three categories: 1) those that induce EMT (i.e. EMT inducers), such as the transcription factors 
Snail, Slug, and Twist; 2) markers of epithelial phenotype (i.e. epithelial markers), such as E-
cadherin and cytokeratin; and 3) markers of mesenchymal phenotype (i.e. mesenchymal 
markers), such as N-cadherin and vimentin.  For cells undergoing EMT, one would expect a 
decrease in expression of epithelial markers, as well as an increase in expression of both EMT 
inducers and mesenchymal markers (2, 14).  
 How can EMT markers be used to assess whether the primary tumor shows evidence of 
containing substantial numbers of cells capable of breaking off?  Prior to undergoing EMT, the 
cancer cells in the tumor remain epithelial cells—albeit abnormal ones—that should exhibit 
typical epithelial-cell levels of EMT markers (high expression of epithelial markers, and low or 
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no expression of EMT inducers and mesenchymal markers).  If the primary tumor, or at least part 
of it, begins generating metastases using the EMT mechanism, it is likely that a steady stream of 
cancer cells in the metastasis-generating portion will undergo the transition.  Once the transition 
is complete for any one cell, the previously-epithelial cancer cell will have become a cancerous 
mesenchymal cell that could detach from the primary tumor and move away from it.  At this 
point the cell would exhibit typical mesenchymal-cell levels of EMT markers (low expression of 
epithelial markers, and high expression of EMT inducers and mesenchymal markers). 
 While in transition, cancer cells will exhibit the “intermediate phenotypes” depicted in 
the middle of Figure 1.  During this time they will be partially epithelial and partially 
mesenchymal, yet still attached to the primary tumor.  Such cells may macroscopically appear to 
remain epithelial but show molecular expression of EMT markers that is abnormal for epithelial 
cells, such as low expression of E-cadherin or high expression of Snail.  Finding cancer cells in 
the primary tumor with molecular expression levels indicative of an intermediate state between 
epithelial and mesenchymal phenotypes would suggest that the primary tumor is generating 
metastases.  Crucially, such measurements could be taken in any primary tumor, regardless of its 
size, stage, or grade, thus satisfying the criterion set forth earlier that new diagnostics of 
metastatic disease measured in the primary tumor should not depend on the established measures 
of lymph node evaluation or imaging. 
 2.4. Public health significance 
 Given that EMT marker expression levels measured in primary tumor cancer cells could 
suggest whether the patient is at high risk for metastatic disease independent of any other 
measurements, there are two ways in which EMT markers could improve CRC outcomes.  First, 
the markers can provide predictive information that can guide therapy.  For example, suppose a 
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primary tumor is discovered that appears to be Stage II by current assessment procedures.  The 
oncologist would likely decide based on current guidelines that surgery alone will suffice to treat 
the tumor and that no systemic chemotherapy is needed (15).  However, if the tumor appears to 
be generating metastases via EMT marker measurements, the oncologist could instead prescribe 
chemotherapy in an attempt to destroy micrometastases that may be present but were not 
detected via imaging or lymph node assessment.  Second, if EMT marker levels in primary 
tumor cancer cells are associated with patient outcomes, then new treatments could be developed 
that target the markers in an effort to hold metastasis in check.  In this report, our concern is 
solely with the use of EMT markers to improve patient risk stratification. 
 Given how closely a CRC patient’s outcome is tied to accurate clinical assessment of 
whether cancer cells have been detaching from the primary tumor, EMT markers hold 
tremendous promise as tools to reduce CRC mortality.  The goal of the present research was to 
assess this promise by estimating associations between EMT marker levels in CRC primary 
tumors at the time of tumor removal and subsequent patient outcomes.  More specifically, we 
sought to do this while designing measurements and analyses that could directly inform and 
facilitate translation of EMT markers to the clinic, where their public health impact stands to be 
realized. 
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Figure 2. Conceptual model of the role of EMT markers in determining CRC patient outcomes 
 
 
 
 
 
 
 
 
 
 
 
 2.5. Systematic review and marker selection 
 2.5.1. Systematic review of literature on EMT markers and CRC outcomes 
 There is no generally agreed upon histopathological definition of EMT (16).  
Consequently, we developed our own approach to measure EMT for this dissertation.  The first 
task was to select which EMT markers to measure in CRC specimens.  To do so, we sought to 
identify original journal articles that measured EMT marker expression levels in clinical CRC 
tumor specimens and related those measurements to patient outcomes.  On 26 October 2012, we 
searched PubMed, EMBASE, and BIOSIS using the same search terms for all databases (see 
Appendix A).  No publication date or language limitations were applied to the search.  The 
searches consisted of four groups of terms: EMT, tumor markers, outcomes, and colorectal 
cancer.  To be captured, an item had to have at least one term from each group. 
 Our searches returned 545 abstracts.  Removing 184 duplicates yielded 361 unique 
abstracts.  I read the 361 abstracts and created a spreadsheet to record the following for each 
abstract: 1) which markers the study examined, 2) whether it looked at cell lines, animals, and/or 
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clinical tissue specimens, 3) whether the paper was a review, and 4) whether it looked at 
outcomes.  Meeting abstracts, reviews, papers not written in English, and studies that only 
looked at animals and/or cell lines were excluded. 
 Based on the 361 abstracts, 122 appeared to have used clinical CRC specimens and 
therefore warranted closer examination.  Inspection revealed that 46 were meeting abstracts and 
1 was a case report.  These 47 were excluded, leaving 75 original journal articles that examined 
EMT markers in CRC tissue specimens.  I then created a second spreadsheet documenting the 
following information for each of the 75 papers: 1) sample size, 2) whether Kaplan-Meier 
survival curves were presented, 3) whether effect estimates such as hazard ratios were calculated, 
4) whether correlations between EMT marker levels and other measurements were presented, 5) 
whether the percent of cases found to have positive expression of EMT markers was provided, 6) 
whether any measures of reliability were reported, and 7) which EMT markers were measured. 
 Thirty papers measured at least one EMT marker in clinical CRC primary tumors and 
evaluated the relationship between EMT marker expression and CRC patient outcomes via either 
Kaplan-Meier analyses or effect estimates.  Between them, these papers measured dozens of 
markers or categories of markers (“categories of markers” meaning, for example, measurement 
of multiple micro-RNAs counts as simply “micro-RNA”).  Because of the sheer diversity of 
EMT markers, we focused on 14 markers and marker categories prominently discussed in the 
EMT literature: E-cadherin, N-cadherin, Vimentin, Snail, Slug, Cytokeratins, Integrins, 
Fibronectin, Twist, ZEB1, ZEB2, Beta-Catenin, TGF-Beta, and Micro RNAs.  We excluded 6 
papers that did not measure at least one of these markers in clinical CRC specimens (17-22), 
leaving a final set of 24 papers that I evaluated for the markers of interest (23-46), though many 
of them measured other markers as well. 
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 For each of the 24 papers, I recorded the following additional information for each EMT 
marker that the paper measured from our selection of 14 markers: whether marker expression 
was measured as protein and/or RNA, how the study defined positive expression for the marker, 
and whether the paper presented Kaplan-Meier analyses stratified by expression levels of that 
particular marker. 
 2.5.2. Marker selection criteria 
 In reviewing the literature, we considered seven criteria for judging whether a particular 
EMT marker might be useful as a clinical tool to assess whether a primary tumor has potentially 
been releasing cancer cells: 
 1. Biological Role: The role of the marker in the EMT mechanism should be well 
understood and critical. 
 2. Percent of subjects with positive expression: A marker that is positive for nearly 0% or 
100% of patients is unlikely to provide much information about the prognosis for different 
patients, given how common metastasis is (47).  Markers for which there are appreciable 
numbers of both marker-positive and marker-negative tumors are likeliest to be clinically useful. 
 3. Reliability: A useful EMT marker for clinical purposes will exhibit a high degree of 
reliability when measured in clinical CRC specimens in the same way.  The reliability of EMT 
markers was difficult to assess because the literature provided little information about both inter-
rater and intra-rater reliability.  Such inconsistencies made comparisons between studies 
difficult, even between studies that measured the same marker using the same laboratory 
technique. 
 4. Validity: To determine the sensitivity or specificity of EMT markers, one would need 
to compare marker expression levels with a “gold standard” measure of whether the patient has 
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metastatic disease.  It was not clear what could constitute such a gold standard in this context.  
Conventional diagnostics of metastatic disease—lymph node evaluation and imaging--are not 
satisfactory because the goal of using EMT markers is to identify those at risk of metastatic 
disease even when no metastases are detected by the other diagnostics.  Correlation between 
EMT marker expression levels and results of the other diagnostics is a helpful, but not definitive, 
demonstration of the validity of an EMT marker for clinical purposes. 
 5. Association with patient outcomes: If the expression levels of a marker play a role in 
generating metastases and the marker is to serve as a clinical indicator of whether the patient is at 
high risk for metastatic disease, then the expression levels should be associated with patient 
time-to-death, that is, the length of time between primary tumor surgery and patient death.  This 
can be assessed using Cox proportional hazards modeling and Kaplan-Meier curves stratified by 
marker expression levels. 
 6. Amount of prior data: Clinical utility ought to be supported by as many studies as 
possible, each of which includes as many subjects as possible.  All else being equal, we had more 
confidence in markers the evidence for which was based on a greater number of subjects. 
 7. Ability to measure the marker: If a marker is difficult to measure accurately in a 
clinical setting, its utility is limited no matter how strong the evidence for it may be according to 
the other criteria described above. 
 2.5.3. Summary of systematic review findings 
 Because most studies measured markers only as protein, results refer to protein 
measurements unless noted otherwise. 
 Beta-Catenin: We found five studies that measured the mesenchymal marker beta-
catenin in CRC tissue (26, 34, 37, 40, 42).  The two that looked at survival by beta-catenin status 
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found no difference in outcomes between marker-positive and marker-negative subjects (34, 40).  
The only study that looked at effect estimates did not find any effect of beta-catenin 
measurements on outcomes (26).  Percent of subjects with positive expression varied, 
particularly by location in the cell (nuclear, cytoplasmic, membranous), but was generally in the 
40-50% range.  Correlations between beta-catenin levels and location in tumor mass were 
inconsistent. 
 Cytokeratins: Of four studies that stained for cytokeratins, two (44, 46) used them only 
as a background stain.  Of the other two studies, one (36) found that cytokeratin-8-positive 
subjects had better survival than cytokeratin-8-negative subjects.  Cytokeratin-14-negative cases 
had better survival than cytokeratin-14-positive cases.  The percent of subjects with positive 
expression was high for cytokeratin-8 (85%) and moderate for cytokeratin-14 (59%).  The last 
study (31) found positive cytokeratin-7 expression in 9% of tumors and no effect on outcomes or 
difference in survival based on cytokeratin-7 expression. 
 E-cadherin: We found 15 papers that measured E-cadherin in clinical CRC tissue.  Of 
these, three that measured protein (31, 34, 41) and one that measured RNA (39) failed to provide 
information on the number of tumors considered marker-positive.  Among the other 11 studies, a 
wide range of definitions of marker-positive status were used (24-27, 29, 35, 37, 38, 42, 43, 45).  
Percent of subjects with positive expression varied but mainly fell between 30 and 70%.  Three 
studies looked at survival by E-cadherin status, with all three finding poorer survival associated 
with reduced E-cadherin expression (24, 29, 43).  Three studies looked at effect estimates, with 
two finding no effect of E-cadherin levels on outcomes (26, 27) and one finding that E-cadherin 
levels do affect patient outcomes (43).  
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 Fibronectin: No paper measured fibronectin levels in clinical CRC specimens and 
related them to outcomes. 
 Integrins: Two papers looked at members of the integrin family of proteins, which are 
mesenchymal markers in the context of EMT. One study found 19% of subjects with positive 
expression for integrin alpha-5-beta-1 and 88% of subjects with positive expression for integrin 
alpha-3-beta-1 but did not look at the association of either protein with outcomes (45).  The 
other, much larger study found 37% of subjects with positive expression for integrin alpha-v-
beta-6 and clear differences in survival and effect estimates for the protein’s relationship with 
outcomes (23).  
 Micro-RNAs: Two papers measured micro-RNAs (miR), but one (39) did not provide 
information on how many tumors were considered marker-positive.  The other study reported 
that subjects with high expression of miR-19b and miR-194 had shorter survival than those with 
low expression (32).  
 N-cadherin: Two studies measured the mesenchymal marker N-cadherin in clinical CRC 
specimens.  One of them that included 10 subjects did not find positive N-cadherin expression in 
any of their tumors, and did not look at the relationship of N-cadherin with outcomes (37).  The 
other study found 44% of subjects with positive expression and, while it did not look at survival 
by N-cadherin status, calculated effect estimates and found no effect of N-cadherin on outcomes 
(26).  However, in the latter study, the 193 subjects were divided into training and testing sets 
before effect estimates were calculated, thus reducing the power for each estimate. 
 Slug: Three studies measured the EMT inducer Slug, though one of them (30) that 
measured RNA failed to provide information on the number of tumors considered marker-
positive.  Of the other two studies, one with a sample size of 10 patients found 30% of subjects 
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with positive expression in primary tumors, and observed no difference in survival by Slug status 
(37).  The other study found 37% of subjects with positive expression (43).  Slug-positive 
patients in this last study had poorer survival than Slug-negative patients, and using hazard 
ratios, the authors concluded that Slug was an independent prognostic factor of outcomes. 
 Snail: Four studies measured the EMT inducer Snail.  Three found 40-55% of subjects 
with positive expression (26, 27, 37) and one found 79% positive (28), though the studies used a 
variety of definitions of Snail-positive status.  The two studies that looked at survival both found 
worse survival in Snail-positive subjects than Snail-negative subjects (28, 37).  The two studies 
that did not look at survival did look at effect estimates, and each obtained mixed within-study 
results (26, 27). 
 TGF-beta: One study measured a member of the TGF-beta class of EMT inducers, 
namely TGF-beta-R2.  It found almost 90% of subjects with positive expression and no 
difference in survival by TGF-beta status (40). 
 Twist: Four studies looked at the EMT inducing Twist family in clinical CRC specimens.  
One study (30) that measured mRNA of Twist1 found that 86% percent of subjects showed 
positive expression and that those with positive expression had worse survival than those with 
negative expression.  Survival differences were especially large among early-stage subjects.  Via 
effect estimates, Twist levels had an effect on outcomes. The other three studies measured 
protein.  One with 10 subjects found 100% of subjects with positive expression but did not look 
at outcomes (37).  The other two studies found roughly 50% of subjects with positive expression 
and did not look at survival (26, 27).  Both calculated effect estimates, with mixed results. 
 Vimentin: Of the four studies that measured this mesenchymal marker, one (39) 
measured mRNA and did not provide information on how many specimens were considered 
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marker-positive.  The other three studies measured protein.  Of these, two (31, 37) found 0% of 
subjects with positive expression—despite using different definitions of marker-positive status—
and another (38) found 9% of subjects with positive expression. 
 ZEB1: In the three studies that measured the EMT inducer ZEB1, two (41, 44) did not 
report percent of subjects with positive expression.  The other found 29% of subjects with 
positive expression and that ZEB1-positive patients had much shorter average survival than 
ZEB1-negative patients (31 months vs. 67 months, respectively) (38).  
 ZEB2: Two studies measured the EMT inducer ZEB2.  One with 10 subjects found 90% 
of subjects with positive expression and did not look at survival or effect estimates (37).  The 
other study found that 48% of the tumors were ZEB2-positive at the tumor invasion front and 
41% were ZEB2-positive at the tumor center (33).  This study reported that 73% of the primary 
tumors had greater ZEB2 expression at the invasion front compared to the tumor center.  ZEB2-
positive patients had poorer survival than ZEB2-negative patients.  In terms of effect estimates, 
ZEB2 levels at the invasion front were a predictor of outcomes, but ZEB2 expression at the 
tumor center was not. 
 2.5.4. Marker selection conclusions 
 Of the three kinds of EMT markers—epithelial markers, mesenchymal markers, and 
EMT inducers—it was not clear that one kind was likelier than the others to be a clinically useful 
predictive tool.  Given budgetary constraints, we could only afford to measure a few markers.  
As a compromise between these considerations, we decided to measure three markers, namely, 
the most promising marker from each category based on prior literature.  
 Epithelial marker: 
 Options: cytokeratin, E-cadherin 
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 Discussion: Effectively, only one study looked at cytokeratin.  Although it provides some 
support for cytokeratin in terms of percent of subjects with positive expression and survival by 
cytokeratin status, this is swamped by the large number of studies on E-cadherin.  The overall 
trend of the results suggests that E-cadherin is a promising marker in terms of percent of subjects 
with positive expression and the marker’s association with outcomes.  Furthermore, its biological 
role in EMT is clear and important, and it is by far the most commonly-studied EMT marker.  
Also, E-cadherin antibody had already been optimized by the UNC Translational Pathology 
Laboratory that performed the benchwork for the project, making E-cadherin more cost-effective 
to measure than cytokeratin. 
 Choice: E-cadherin 
 Mesenchymal marker: 
 Options: beta-catenin, fibronectin, integrins, N-cadherin, vimentin 
 Discussion: There was no relevant data about fibronectin.  The data strongly suggest that 
beta-catenin is not a good marker based on lack of association with outcomes and an inconsistent 
percent of subjects with positive expression.  Likewise, the data do not support vimentin based 
on its percent of subjects with positive expression of 0% or close to it, as well as the lack of 
information about whether it is associated with outcomes. 
 The two best candidates are N-cadherin and integrins, specifically integrin alpha-v-beta-
6.  N-cadherin is appealing because it plays an important biological role in the EMT mechanism 
(part of “cadherin switch” with E-cadherin) and in mesenchymal cell motility.  In the one 
meaningful study that measured N-cadherin (the other study being tiny), the percent of subjects 
with positive expression was right where one would want it to be (44%).  The effect estimates of 
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its association found nothing, but the sample sizes involved in the calculations were not large 
(roughly n=100). 
 Two of the three integrins on which we have any data are not serious candidates; only 
integrin alpha-v-beta-6 is.  The percent of subjects with positive expression and clear association 
with outcomes in the one large study provide stronger support than N-cadherin received from its 
one relevant study.  Integrin alpha-v-beta-6 and N-cadherin have similar biological roles as 
membrane-bound proteins that help mesenchymal cells move through their environment.  All 
told, integrin alpha-v-beta-6 is the stronger option.  However, the prior study that measured this 
integrin in CRC primary tumors did so by measuring only the beta-6 sub-unit and then making 
an inference from that to the alpha-v-beta-6 complex (23).  To make our study comparable, we 
decided to measure only the beta-6 sub-unit as well. 
 Choice:  Integrin beta-6 
 EMT inducer: 
 Options: Slug, Snail, TGF-beta, Twist, ZEB1, ZEB2 
 Discussion: TGF-beta was dismissed because the one study that measured it gave clear 
evidence that it is not a good marker.  The evidence was similar and moderately supportive for 
the other five options.  Each was measured in 2-4 studies, with a mixture of results suggesting 
that the marker is and is not associated with outcomes.  Considering all of our selection criteria, 
Snail seemed the best choice because it was measured in the greatest number of studies, 
generally had ideal percentages of subjects with positive expression, and had as much evidence 
showing an association with outcomes as any of the other candidates. 
 Choice: Snail 
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CHAPTER 3. METHODS 
 3.1. Subject selection and enrollment 
 3.1.1. Study population 
 The Cancer Care Outcomes Research and Surveillance Consortium (CanCORS) study 
was undertaken by a consortium of seven teams of investigators across the United States (48).  
Their aim was to study the impact of the characteristics of healthcare delivery systems, patient 
characteristics, and patient beliefs on cancer outcomes.  The study was a population-based, case-
only prospective cohort of lung and colorectal cancer patients.  Subjects were enrolled between 
2003 and 2006.  Every site collected patient surveys, physician surveys, and medical records 
data.  Subjects completed surveys at baseline, 12 months after baseline, and 5 years after baseline 
(49).  Upon enrollment, each subject identified a proxy respondent who completed the next 
follow-up survey in the event of the subject’s death or inability to complete the survey. 
 The patient surveys asked questions on a range of topics, including demographics, 
treatments received (surgery, radiation, chemotherapy), quality of life, and health history and 
behaviors.  Tumor specimens were collected only among North Carolina subjects.  Since the 
main exposures of interest in this dissertation were primary tumor expression levels of EMT 
markers, our study sample was limited to NC subjects for whom tumor tissue was available. 
 The NC site was based at the University of North Carolina at Chapel Hill (UNC).  It 
enrolled 990 incident colorectal cancer (CRC) cases during the CanCORS enrollment period (50) 
that were drawn from 33 counties in eastern and central NC (51).  These subjects constitute a 
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population-based, case-only prospective cohort of incident CRC cases from the 33 counties in 
2003-06. 
 3.1.2. Subject identification, recruitment, and enrollment 
 During the enrollment period, incident CRC cases were identified using a rapid-case 
ascertainment protocol through the NC Central Cancer Registry, to which all new cases of CRC 
in the study region must be reported (52).  Of 1,899 nominally eligible case reports, 350 were 
found to be ineligible and 43 could not be contacted due to physician refusal.  Of 1,506 eligible, 
contactable cases, 326 refused to participate, 77 could not be reached, and 85 were not capable of 
giving consent and had no proxy to participate in their stead.  This left 1,018 cases who agreed to 
be interviewed, provide medical record data, or both, giving a response proportion of 
1,018/1,506 = 67.6%.  Of the 1,018 eligible subjects who agreed to participate, 28 did not end up 
enrolling for unspecified reasons, giving the final UNC study sample of 990. 
 Whenever possible, the patient survey was administered to the patient or to a proxy 4 
months from the date of diagnosis.  Information from all patients selected for contact was 
included in the data from the cohort, regardless of the survival status of the patient.  For patients 
who died by the time of initial contact or before the time of a scheduled interview, attempts were 
made to interview an eligible proxy or surrogate. 
 If the patient was not able to complete an interview, a surrogate had to be interviewed 
instead.  Eligibility criteria for surrogates were: at least 18 years old; patient gave consent for 
investigators to speak with the surrogate or the patient is dead; the patient indicated that the 
surrogate knows best how the patient has done since diagnosis; and the surrogate had to reside in 
one of the 33 counties in the study region. 
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 Of the 990 subjects enrolled in NC, 506 subjects (51%) provided tumor specimens.  The 
major reasons for not obtaining tumor tissue from all study subjects were that subjects did not 
consent to donate tumor tissue, and among those who did consent to give tissue, adequate tumor 
blocks for research were not always available after surgery.  Our study sample for the 
dissertation was a subset of the 506 NC subjects who provided tumor specimens. 
 3.1.3. Subject eligibility criteria 
 Inclusion criteria were as follows (52): 
  a) Sex: males and females eligible 
  b) Age: 21 years or older at time of diagnosis 
  c) Race: no exclusion based on race/ethnicity 
  d) Residence: At the time of diagnosis and initial contact, patient had to be a  
   resident of one of the 33 counties constituting the study region. 
  e) Language: Able to complete study interviews in English, Spanish, or Chinese 
  f) Cancer Diagnosis:  A histologically-confirmed diagnosis of colorectal cancer  
   on 1 January 2003 or later.  All stages of disease except in situ were  
   eligible. 
 3.2. Specimen collection 
 3.2.1. Collection at clinics 
 Tumor specimens were collected at the clinics across NC that performed cancer surgery 
on enrolled subjects.  Portions of these tumors were transported to UNC.  Tumor samples were 
fixed in formalin and embedded in paraffin after surgical removal (53).  Since this initial tissue 
preparation was performed at different hospitals and clinics throughout the study region, there 
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may have been variation in terms of fixation protocols, time from tumor removal to fixation, 
storage conditions at the clinic, and technician skill. 
 During the CanCORS data-collection period, investigators were informed via the rapid-
case ascertainment system of new, nominally-eligible incident cases of CRC within the study 
region.  Investigators checked the pathology report of each case to confirm eligibility (54).  For 
example, they ensured that the diagnosis was for invasive carcinoma since in situ tumors were 
not eligible.  After confirming patient eligibility, investigators requested tumor blocks from the 
hospital or clinic that performed the patient’s cancer surgery.  The goal was to obtain two blocks 
of tumor tissue and two blocks from the tumor margins per patient, the latter including adjacent 
normal tissue (55).  Biopsies and metastases were not requested.  When the primary tumor had 
spread to an adjacent organ beyond the colon or rectum (but without metastasizing), investigators 
obtained normal tissue from the adjacent organ. 
 3.2.2. Specimen preparation and storage at UNC 
 Upon receiving a patient’s tumor blocks at UNC, investigators cut the tissue to prepare 
histology slides, which were then stained with hematoxylin and eosin (53).  A trained pathologist 
verified which parts of a stained slide were normal or tumor.  The tissue was then incorporated 
into a tissue microarray (TMA) along with tissue samples from other subjects.  Using the 
pathologist’s indications on the stained slides as to which parts of tissue samples were normal 
and which were tumor, a TMA technician punched cores of normal and tumor samples from a 
given patient’s blocks.  Most patients had six cores on a TMA: 3 cores of normal tissue and 3 
cores of tumor tissue.   Some patients had more or less than 3 cores of a given tissue type.  
Tissue slides for the dissertation were prepared from the TMAs. 
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 Once prepared, TMAs were stored at 4 degree Celsius (54).  Slides cut from the TMA but 
left unstained for future use were stored at -80 degrees Celsius.  Any unused tissue was returned 
to the hospital or clinic from which it was obtained. 
 3.2.3. Control specimens 
 Tissue specimens for positive and negative controls were obtained from the Funkhouser 
Laboratory in the UNC Department of Pathology and Laboratory Medicine.  Positive control 
specimens were colorectal tumor tissue and negative control specimens were normal (tumor-
free) colorectal tissue.  Controls came from UNC patients who were not enrolled in CanCORS. 
 3.2.4. Sample size 
 The specimens of the 506 CanCORS participants who provided CRC tissue samples were 
distributed across 56 TMAs stored at the Keku Laboratory.  To minimize costs and use of 
specimens, the dissertation committee recommended staining slides from a subset of subjects 
large enough to provide a reasonable chance of observing a substantial hazard ratio estimate.  If 
little variation was found for a particular marker in a sufficiently large subset, this could suggest 
that the expression levels of the marker likely are not able to distinguish between tumors that are 
behaving differently from each other (47), assuming the sample includes a mixture of tumors 
with high and low levels of cancer cell detachment.  Logically, this would imply that it was not 
worthwhile to measure a marker with a narrow expression distribution in more subjects. 
 Many of the TMAs containing CanCORS subject specimens also contain specimens 
collected for another study (the Rectal Study).  Some subjects were enrolled in both CanCORS 
and the Rectal Study; such individuals were treated as CanCORS subjects.  Random selection of 
TMAs for the subset might have resulted in selecting TMAs containing only one or two 
CanCORS subjects, which would have been an inefficient use of resources.  For greater 
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efficiency, we selected TMAs from among those containing the greatest number of CanCORS 
subjects so that a minimal number of TMAs had to be stained to provide the desired sample size. 
 Table 1 shows the results of sample size calculations using PROC POWER in SAS.  The 
parameters used in the calculations were based on the E-cadherin, Integrin, and Snail results 
from the systematic literature review (see Section I.E).  From the literature overall, a 30% 
proportion of patient deaths within 5 years of surgery in the unexposed (those with non-EMT-
like marker expression levels) seemed reasonable and the analysis of the subset aimed to achieve 
80% power.  As Table 1 indicates, this meant the analysis should have a sample size of at least 
165 subjects. 
Table 1. Sample size calculations for initial selection of subjects* 
% outcomes (deaths) 
In unexposed (those with 
Non-EMT marker levels) 
Statistical Power 
70% 80% 90% 
20% 190 240 325 
30% 130 165 220 
40% 100 130 170 
*Total sample size for 70%, 80%, or 90% power to detect a hazard ratio of 2.00 across 5 years of 
follow-up, for 40% exposed (i.e. EMT-like marker levels) and with varying percentages of 
outcomes (deaths) in unexposed (i.e. non-EMT-like marker levels) over the 5-year window, with 
a 2-sided alpha of 5%. 
 
 In anticipation of possible laboratory error when handling the tissue samples, specimens 
from 236 subjects across 13 TMAs with large numbers of CanCORS subjects were prepared for 
staining.  One TMA with specimens from 17 subjects could not be used because the position of 
cores on the tissue section did not match the map for the TMA, making it impossible to 
determine the identity of the cores.  This reduced the available sample size to 219 subjects.  To 
be included in the study sample, subjects had to have at least one core of tumor tissue 
successfully stained for one marker, with that core having at least 50 epithelial cells and 
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unambiguous histology.  From the 12 TMAs, we excluded 26 subjects lacking adequate tumor 
tissue and an additional 3 subjects who could not be linked to medical records data, yielding a 
final study sample of 190 subjects. 
 Figure 3 shows the overall flow of subject inclusion from nominally-eligible CRC cases 
to the final study sample. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
27 
 
Figure 3. Flow of patient eligibility and inclusion 
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3.3. Specimen staining 
 3.3.1. Acquisition of antibodies for immunohistochemistry 
 The following antibodies were purchased: 
  a) E-cadherin: Mouse monoclonal ready to use (RTU), clone 36B5  
   (cat #PA0387) from Leica Microsystems Inc. (Norwell, MA)  
  b) Integrin beta-6: Goat polyclonal (sc-6632) from Santa Cruz    
   Biotechnology (Dallas, Texas) 
  c) SNAIL1: Goat polyclonal (ab53519) from Abcam (Cambridge, MA) 
 3.3.2. Immunohistochemistry staining procedures 
 Immunohistochemistry (IHC) was performed at the UNC Translational Pathology 
Laboratory (TPL) using the Bond fully-automated slide staining system (Leica Microsystems 
Inc., Norwell, MA).  Slides were deparaffinized in Bond Dewax solution (AR9222) and hydrated 
in Bond Wash solution (AR9590). Antigen retrieval was performed at 100C for Integrin beta-6 
and Snail (for 20 minutes or 30 minutes, respectively) in Bond-epitope retrieval solution 1 at pH 
6.0 (AR9961) and for E-cadherin for 20 minutes at 100C in solution 2 at pH 9.0 (AR9640).  
After pretreatment, anti-E-cadherin was applied for 15 minutes, anti-Snail (1:200) for 30 minutes 
and anti-Integrin beta-6 (1:100) was applied for 1 hour. 
 Detection of Snail and Integrin beta-6 was performed using the Bond Intense R Detection 
System (DS9263) supplemented with the LSAB+ kit (DAKO, Carpinteria, CA).  E-cadherin 
detection used the Bond Polymer Refine Detection System (DS9800).  Stained slides were 
dehydrated and cover-slipped.  Positive and negative controls (no primary antibody) were 
included for each antibody.  All assays were single-marker (i.e. no multiplex assays). 
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 Stained slides were digitally imaged at 20× magnification using the Aperio ScanScope 
XT (Aperio Technologies, Vista, CA).  Digital images were stored in the Aperio Spectrum 
Database.  Example images of staining and annotations are provided below in Figures 4-6. 
 
Figure 4. Immunohistochemistry examples for positive and negative staining for each of E-
cadherin, Integrin beta-6, and Snail 
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Figure 5. Illustration of Tissue Studio analysis of colon tumor tissue 
 
 
 
 
 
 
 
 
 
 
 
(A) Original image of TMA core stained for E-Cadherin.  Bar = 300um. (B) Green lines show manual 
annotation of tumor areas on image (C) Mark-up of image by Tissue Studio Composer. The algorithm 
was trained to differentiate between epithelial and stromal regions.  Orange highlighted areas are 
enriched in epithelial cells and closely match the regions that were manually annotated in (B).  Blue 
highlighted areas are enriched for stromal cells.  Only the epithelial enriched regions were analyzed.  
(D) Mark-up of analysis results for tumor tissue.  Blue= IHC negative, yellow = 1+, orange = 2+, red = 
3+ (staining intensity).  This tumor tissue core has high concentrations of E-Cadherin, with most of the 
staining classified as 3+ in intensity. 
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Figure 6. Illustration of Tissue Studio analysis of normal colon tissue 
 
(A) Original image of TMA core stained for E-Cadherin.  Bar = 300um. (B) Green lines show manual 
annotation of colon crypt areas on image (C) Mark-up of image by Tissue Studio Composer. The 
algorithm was trained to differentiate between epithelial and stromal regions.  Orange highlighted areas 
are enriched in epithelial cells and closely match the regions that were manually annotated in (B).  Blue 
highlighted areas are enriched for stromal cells.  Only the epithelial enriched regions were analyzed.  (D) 
Mark-up of analysis results for normal tissue.  Blue= IHC negative, yellow = 1+, orange = 2+, red = 3+ 
(staining intensity).   
 
 3.4. Digital image annotation and analysis 
 3.4.1. Annotation rationale and goal 
 Tumors contain not only cancer cells but numerous other kinds of cells, including 
fibroblasts, endothelial cells, cancer stem cells, and immune cells (Figure 7) (11).  Metastases 
form from a subset of the cancer cells within a primary tumor and not from the other cell types.  
However, EMT markers may be expressed—or not expressed—by all types of cells found in a 
tumor.  Thus, when digital slide images are scored by computer, results could be misleading if 
the entire image is scanned when not all of the cells are cancer cells.  Since only EMT marker 
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expression of cancer cells is relevant to determining whether the tumor has been producing cells 
capable of acting as metastases, images must be marked (i.e. annotated) prior to scanning to 
restrict the computer’s analysis of marker expression to cancer cells. 
 The goal of image annotation was to mark images prior to scoring such that all cancer 
cells in the image would be included in the analysis of marker expression while all other cells 
would be excluded. 
Figure 7. Reductionist and heterotypic representations of cancer tumors (from Hanahan and 
Weinberg, 2000) (11) 
 
 
  3.4.2. Image annotation and scoring procedures 
 Computer algorithms annotated and scored every eligible tissue core to obtain continuous 
marker expression data.  Continuous expression data were sought because marker expression is 
inherently continuous.  In addition, continuous data provided maximum flexibility in identifying 
a clinically-useful cut point to define dichotomous marker expression status, the latter reflecting 
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the binary nature of treatment decisions.  We used approximately 65 cores originating from two 
TMAs for algorithm training and automated-analysis validation.   
 Definiens Composer Technology (Tissue Studio version 2.1.1 with Tissue Studio Library 
version 3.6.1; Definiens Inc., Carlsbad CA) was used to identify regions enriched in epithelial 
cells in IHC-stained TMA cores.  To detect differences in cell shape and tissue structure, we 
developed two Composer algorithms per marker—one for cores containing normal adjacent 
tissue and a second for tumor cores—as both types of tissue were present on each TMA.   
 After Composer training, we developed two Tissue Studio scoring algorithms 
(“solutions”) per marker.  Different Composers were used to identify epithelial cell regions but 
identical settings were used to determine relative DAB staining intensity.  The 
Composer_MarkerArea Solution was used to detect E-cadherin staining.  This algorithm gave 
average intensity readings for each core on a continuous scale of 0-3 and included both 
membrane and cytoplasmic E-cadherin staining.   Integrin beta-6 membrane staining was 
detected using the Composer_Nuclei_Membranes&Cells Solution.  We used the 
Composer_Nuclei(Positive_vs_Negative) Solution to detect nuclear Snail expression.  Integrin 
beta-6 and Snail were measured as core percent positive cells (Integrin) or nuclei (Snail) on a 
continuous scale of 0-100. 
 To evaluate the reliability of computer annotations, I used Aperio ImageScope (version 
11.2; Leica Biosystem, Buffalo Grove, IL) to manually annotate the same 65 cores per marker 
that were used to optimize Tissue Studio solutions.  Included regions were marked with the 
positive pen and excluded regions were marked with the negative pen.  I remained blind to 
patient and tumor characteristics while annotating.  This was accomplished by keeping TMA 
data and identification numbers separate from other CanCORS data and identification numbers 
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until after annotation was finished.  As part of the original CanCORS study design, TMAs and 
the rest of the subject data were assigned different identification numbers and could only be 
brought together by use of a linking file.  I did not have access to a linking file until after 
annotating the specimen images, which kept me from connecting any specimen images or data 
with other subject data. 
 The manually-annotated cores—considered the gold standard for digital separation of 
tissue types—were then analyzed using appropriate Aperio scoring algorithms (Membrane v9 
algorithm for E-cadherin and Integrin beta-6, Nuclear v9 algorithm for Snail). Automated scores 
obtained via manual and automated annotation produced Pearson correlations of 0.91 for E-
cadherin, 0.88 for Integrin beta-6, and 0.94 for Snail.  Having verified the accuracy of the 
annotation algorithms for the three markers, all 12 TMAs stained for E-cadherin, Integrin beta-6 
and Snail were analyzed (36 slides in total). 
 Subjects typically had multiple cores available of a given tissue type (tumor or normal).  
To assign an expression value for each subject by marker and tissue type, we handled replicate 
cores in two ways: first, as a weighted average of cores, and second, by assigning the expression 
value of the subject’s “worst” core as the marker expression value.  For weighted averages, the 
weights were area analyzed for E-cadherin, number of cells for Integrin beta-6, and number of 
nuclei for Snail.  The worst score by tissue type was assigned as the lowest core average intensity 
for E-cadherin, as the highest core percent positive cells for Integrin beta-6, and as the highest 
core percent positive nuclei for Snail. 
 After observing unexpected results when comparing mean Snail expression in tumor 
tissue to normal tissue, we trained two additional Snail scoring algorithms on a different TMA 
than the one used to develop the original scoring algorithms: a second nuclear algorithm and a 
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whole-cell algorithm that scored Snail expression in any part of a cell.  These additional Snail 
scoring algorithms measured expression on a continuous percent positive scale and were applied 
to all 12 TMAs.  The results of the two additional Snail algorithms were qualitatively similar to 
those from the original nuclear algorithm.  Thus, for analysis we used only Snail expression 
values based on the original algorithm. 
 Examples of manual and automated annotations are given for tumor tissue (Figure 5) and 
normal tissue (Figure 6). 
 3.4.3. Linkage of marker data with main CanCORS data 
 After image analysis, the CanCORS database manager (Christopher Martin) provided a 
file linking TMA identification numbers with CanCORS identification numbers.  Marker data 
and general CanCORS data (surveys, medical records) were merged via the linking file to 
provide a complete set of variables.  CanCORS subjects for whom EMT markers were not 
measured were dropped, leaving a final working dataset with all variables and containing only 
the subset of CanCORS subjects in whose tumor specimens EMT markers were measured. 
 3.5. Assessment of reliability 
 The public health significance of measuring EMT markers in primary tumors lies in their 
potential clinical use as tools to stratify patients according to risk for worse outcomes.  Clinical 
usefulness depends in part on marker reliability, which is how closely repeated measures of the 
marker in the same specimen match each other.  Two kinds of reliability could be considered.  
First is inter-rater reliability, the consistency of measurements when different people score the 
same specimens.  Second is intra-rater reliability, the consistency of measurements when the 
same person scores a specimen multiple times. 
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 In this research we evaluated a form of inter-rater reliability.  In theory, this could be 
applied at each of two steps: annotation and scoring.  The only scoring that was performed was 
the automated scoring described above.  Thus, computer programs were the only scoring rater 
and no test of scoring reliability was possible given the lack of manual scoring. 
 We did, however, assess the inter-rater reliability of annotation.  The primary rater in this 
case was the set of computer algorithms developed to perform automated annotation as described 
above.  Such annotation was applied to all eligible cores in the EMT dataset.  I served as 
secondary rater with my manual annotations of a subset of eligible cores.  The roughly 65 cores 
that were annotated by computer and also manually constituted our reliability sample. 
 After both sets of annotations were complete, the same automated scoring algorithms 
were applied to each set to generate image scores.  These scores—the automated annotation of a 
given image paired with the manual annotation of the same image—could then be compared by 
Pearson correlations to measure the reliability of the automated annotations. 
 As stated earlier, these correlations were 0.91 for E-cadherin, 0.88 for Integrin beta-6, 
and 0.94 for Snail.  These high correlations suggest that the automated annotations were 
excellent approximations of the gold-standard manual annotations. 
 3.6. Statistical analysis for time-to-event analysis 
 3.6.1. Overview 
 The clinical and public health benefit of an EMT marker would be as a diagnostic of 
metastatic disease in addition to lymph node evaluation and radiologic imaging.  Introducing a 
marker into clinical practice would require first determining whether it provides useful 
information beyond what is provided by established prognostic and predictive factors.  The most 
important aspect of this is whether marker expression levels are associated with patient mortality 
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in the form of length of time from surgery to death, independent of relevant confounders.  
Addressing this issue for our selected EMT markers was the goal of our time-to-event analysis. 
 While marker expression is inherently continuous, an EMT marker would be used to 
make a clinical decision, which is inherently binary.  Therefore, the association of interest is 
between dichotomous marker expression and time-to-death, not the association between 
continuous marker expression and time-to-death.  However, the best way to define dichotomous 
marker expression is to initially measure continuous marker expression for all subjects, then 
identify a clinically-informative cut point along the continuum to classify each individual as 
marker-positive or marker-negative. 
 3.6.2. Definitions 
 Primary Exposures of Interest: EMT marker protein expression levels in the biologically-
relevant portions of cancer cells in CRC primary tumor tissue at the time of tumor removal 
surgery.  “Biologically-relevant portions of cancer cells” meant membrane expression for E-
cadherin and Integrin beta-6, as well as nuclear expression for Snail.  Marker expression is 
inherently continuous and was initially measured as such.  For translational purposes, the 
relevant form of marker expression is dichotomous (marker-positive versus marker-negative) 
based on a clinically-informative cut point along the original continuum.  This is because the 
markers have to be used to make clinical decisions, which are inherently binary.  Thus, the 
primary exposures of interest were dichotomous tumor expression variables for each marker. 
 Outcome of Interest: Time from tumor removal surgery until all-cause mortality.  Vital 
status for all subjects was verified using the Social Security Death Index on 4 May 2010, 
providing at least 42 months of follow-up observation per individual.  The Index records all 
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deaths in the United States, though typically individuals are not entered until two years after their 
deaths. 
 Censoring: Subject follow-up time was administratively censored at 5 years after surgery. 
 Truncation/Immortal Person-Time: An individual could not participate in this analysis 
without providing tumor tissue.  Furthermore, specimens could not be provided to the study until 
tumor removal surgery.  Therefore, all time from a subject’s birth until the date of tumor removal 
was immortal time and was not included in the analysis.  This meant we excluded individuals 
who died before tumor removal.  The “origin” time point for each subject was the date of tumor 
removal. 
 Loss to Follow-Up and Withdrawals: A subject was lost to follow-up if vital status as of 4 
May 2010 could not be assigned.  A subject could have died without being recorded in the Death 
Index if the Index had not yet recorded the date of death, which might have happened to any 
subjects who died after 2008.  For withdrawals, consulting the Death Index allowed verification 
of vital status even if the subject had withdrawn from the study.  In practice, all subjects who 
were not verified as dead as of 4 May 2010 were last observed at a time more than 5 years after 
surgery.  This meant that no outcomes were missing due to loss to follow-up or withdrawals. 
 3.6.3. Descriptive statistics 
 For categorical variables, distributions of demographic, tumor, and treatment 
characteristics were determined using PROC FREQ and presented as frequencies and 
percentages.  For continuous variables, subject characteristics were calculated using PROC 
TTEST and presented as means and standard deviations. 
 The EMT study sample represents a 10% sample of all nominally-eligible CRC cases in 
the catchment area during the enrollment period (190/1,899), a 19% sample of all NC-CanCORS 
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subjects (190/990), and a 38% sample of NC-CanCORS subjects who provided tumor tissue 
(190/506) (Figure 3).  This raises the question of whether the EMT study sample remains 
representative of the underlying source population of CRC cases.  The question cannot be 
answered definitively because doing so would require comparing the EMT subjects to all 
nominally-eligible CRC cases across an effectively-infinite number of personal characteristics, 
such as exhaustive considerations of genetics, environmental exposures, life experiences, and 
socioeconomic status.  The difficulty in addressing this is especially great for nominally-eligible 
cases who did not enroll in CanCORS because detailed information on them is not available. 
 Since a great deal of information is available for all CanCORS subjects—not just those in 
the EMT sample—it is possible to compare subject characteristics for overall CanCORS subjects 
to the EMT sample.  This allows some assessment of whether the EMT sample remains 
representative of all enrolled CanCORS subjects.  Consequently, descriptive statistics were 
obtained for both the EMT sample and overall CanCORS.  To formally test whether the 
distributions of the two samples for a given characteristic were different to a statistically-
significant degree, chi-square tests were used for categorical variables and t-tests for continuous 
variables.  P-values less than 0.05 were considered evidence that the EMT sample differed from 
overall CanCORS for the variable in question; p-values of 0.05 or above suggested that the two 
samples were reasonably similar to each other. 
 I also examined the distributions of the expression of each EMT marker in both normal 
and tumor tissue.  This was done for the original continuous expression variables that were 
obtained directly from the data collection and therefore PROC TTEST was used to obtain means 
and standard deviations.  For each marker expression variable, I used unpaired two-sample t-tests 
to compare expression in normal tissue to tumor tissue.  The EMT mechanism sets up clear 
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expectations of how expression levels in the two tissue types should relate to each other: 
compared to normal, tumor tissue should have, on average, lower E-cadherin expression and 
higher Snail and Integrin beta-6 expression.  Comparing expression in normal tissue versus 
tumor allowed me to assess whether these expectations were met in the observed data. 
 3.6.4. Identification of statistically-optimal cut points of marker expression 
 The data collection yielded six continuous marker expression variables: weighted average 
and worst score for each of Snail, E-cadherin, and Integrin beta-6.  For each variable, I wished to 
identify the cut point distinguishing marker-positive status from marker-negative that was most 
strongly associated with time-to-death. 
 For every possible cut point along any marker expression continuum, I defined marker-
positive status as expression at or above the cut point and marker-negative status as expression 
below the cut point.  Thus, marker-positive always meant high expression and marker-negative 
always meant low expression.  Whether marker-positive status is clinically desirable depends on 
the particular marker.  E-cadherin-positive status would be expected to correlate with better 
outcomes (i.e. longer time-to-death) (2, 5, 56), whereas Snail-positive (2, 5) or Integrin beta-6-
positive (23) status would be expected to correlate with worse outcomes. 
 To identify the statistically-optimal cut point for each continuous marker expression 
variable, I used a SAS macro to assess the model goodness of fit for a series of bivariate 
associations between dichotomous marker expression status and time-to-death.  The macro 
iteratively dichotomized marker expression at every possible cut point in the observed tumor 
tissue data, with each cut point corresponding to a different subject’s expression value. Each 
dichotomization of marker expression status was fit as the only independent variable in a Cox 
model with time-to-death as the outcome, producing a Bayesian Information Criterion (BIC) 
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model fit statistic.  The expression value with the lowest BIC statistic was considered the 
statistically-optimal cut point for that marker expression variable. 
 This approach is an alternative to receiver operating characteristic curves (ROC).  Both 
methods can be used to select a cut point along a continuum of marker expression values based 
on a criterion that relates marker expression to patient outcomes.  The methods differ in two 
important respects.  
 First, the form of subject outcomes is different.  ROC curves use a binary outcome of 
whether a subject died (yes/no) while our approach uses continuous time-to-death.  It matters 
whether a patient died 5 months or 50 months after surgery.  ROC curves do not account for such 
distinctions whereas our approach does. 
 Second, the criterion used to identify a cut point differs between the methods.  In ROC 
curves, the cut point selected is typically the one corresponding to the most upper-left-hand point 
on a plot of sensitivity versus (1 – specificity) (i.e. true positive rate versus false positive rate).  
In our approach, the statistically-optimal cut point is the one yielding the best model fit in a 
bivariate proportional hazards model of dichotomous marker expression and continuous time-to-
death. 
 This difference between cut point selection criteria implies a difference in interpretation 
between the two methods.  Being based on measures of sensitivity and specificity, the cut point 
selected by an ROC curve is usually interpreted as the one that should be implemented clinically.  
When a cut point is selected in the upper-left-hand corner of the ROC curve, the presumption is 
that false positives and false negatives have clinical consequences of roughly equal importance, 
which is not always true.  In contrast, the optimal cut point in our approach is a statistical 
measure of the largest difference in the observed data between hazard functions for marker-
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positive and marker-negative subjects.  Thus, the direct application of our method is to determine 
whether an association exists between marker expression and time-to-death.  The statistically-
optimal cut point might or might not be judged to be best for clinical use, but that determination 
requires consideration of additional information besides model fit alone. 
 For macro SAS code and further details about our approach, see Appendix B. 
 3.6.5. Bivariate time-to-event analysis 
 The optimization macro was used to identify the statistically-optimal cut point in the 
observed data for each of the six continuous marker expression variables.  On the average 
intensity scale of 0-3 for E-cadherin, we found that the statistically-optimal cut point was about 
0.52 for weighted averages and 0.42 for worst cores.  On a percent positive cells scale for 
Integrin beta-6, the optimal cut point was about 9.4% for weighted averages and 7.7% for worst 
cores.  On a percent positive nuclei scale for Snail using the first nuclear scoring algorithm, the 
optimal cut point was about 25.2% for weighted averages and 63.6% for worst cores.  This 
information was used to create dichotomous expression variables defined by these cut points.  I 
performed bivariate analyses of the relationship between dichotomous marker expression and 
subject survival by generating marker expression-stratified Kaplan-Meier survival curves. 
 The Kaplan-Meier or product limit estimator of survival is given by 
 S(t) = Productti<t[ 1 – (di/ ni) ] 
where S(t) is the probability of a member of a given population having a lifetime exceeding time 
t, ni is the number of subjects at risk for the event of interest (here: death) just prior to time ti, and 
di is the number of deaths at time ti (57).  I used PROC LIFETEST to generate Kaplan-Meier 
survival curves among subjects in our dataset stratified by dichotomous marker expression 
status.  This involved the use of each subject’s recorded time from surgery to death or last 
 
 
43 
 
observation, as well as information as to whether the subject’s observation time was censored at 
5 years after surgery.  Differences in survival between subjects in different strata of marker 
expression status were tested for statistical significance using the logrank test, using a 
significance threshold of 0.05. 
 Stratified survival curves were generated by stratifying on the following sets of variables: 
 a) E-cadherin weighted average 
 b) E-cadherin worst core 
 c) Integrin beta-6 weighted average 
 d) Integrin beta-6 worst core 
 e) Snail weighted average 
 f) Snail worst core 
 g) Jointly by E-cadherin weighted average and Integrin beta-6 weighted average 
 h) Jointly by E-cadherin worst core and Integrin beta-6 worst core 
 i) Jointly by E-cadherin weighted average and Snail weighted average 
 j) Jointly by E-cadherin worst core and Snail worst core 
 k) Jointly by Integrin beta-6 weighted average and Snail weighted average 
 l) Jointly by Integrin beta-6 worst core and Snail worst core 
 In addition to Kaplan-Meier estimation, I also performed bivariate time-to-event analysis 
using Cox proportional hazards modeling.  The survivor and hazard functions are equivalent and 
are related by the formula  
 h(t) = -d/dt [log S(t)] 
where h(t) is the hazard function and S(t) is the survivor function (57).  Thus, one would expect 
bivariate Cox models to produce the same results, in different form, as Kaplan-Meier estimates.  
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The bivariate Cox models were run using PROC PHREG and included dichotomous marker 
expression as the only independent variable in a model with outcome of time-to-death.  Subjects 
were administratively censored at 5 years after surgery in Cox models as they were in Kaplan-
Meier estimates. 
 3.6.6. Covariate selection 
 The ultimate goal of our time-to-event modeling was to produce valid estimates of the 
association between each dichotomous marker expression variable and time-to-death.  Achieving 
that validity requires, among other things, that confounding of the association of interest by other 
variables be controlled so as not to bias the association of interest (58).  Thus, our most valid 
estimates of the association between dichotomous marker expression and death are those 
adjusted for sources of confounding, insofar as those sources can be discerned. 
 Past studies of associations between EMT marker expression in primary tumors and 
patient outcomes were not consistent in terms of what covariates they adjusted for in multivariate 
models (5).  None of them provided a justification for their decisions.  To identify the most valid 
adjustment set possible supported by a reasonable rationale, we selected covariates for our 
multivariate Cox models based on the results of past studies, considerations of biological 
plausibility, and directed acyclic graph (DAG) theory (59). 
 Figure 8 (below) presents our DAG showing postulated causal relationships between the 
exposure (observed primary tumor cancer cell EMT marker expression), outcome (time from 
surgery to death), and other relevant variables. 
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Figure 8. Directed acyclic graph (causal diagram) depicting postulated relationships between 
primary tumor cancer cell EMT marker expression, time-to-death, and other variables  
 
 
Before describing the consequences of the postulated relationships among the variables, 
the presentation of the DAG should be clarified.  Several nodes contain multiple variables.  This 
is done solely to streamline the presentation.  For each node with multiple variables—say, the 
one containing both M-stage and N-stage—putting the variables in the same node merely 
indicates that each of these variables is thought to have the same relationships with ancestor and 
descendant nodes as every other variable in the node.  Variables “sharing” a node should be 
considered independent of each other apart from sharing the same ancestors and descendants. 
 The measured association of interest is that between Observed EMT and Time from 
Surgery to Death.  Elimination of confounding requires adjusting for a set of covariates that will 
“block” any open paths of association between the main exposure and outcome other than the 
path leading directly from the main exposure to the outcome.  These alternate paths of 
association that must be blocked by adjustment are known as “backdoor paths,” which are open 
paths connecting the main exposure to the outcome while including an arrow head pointing into 
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the main exposure (59).  In this case, there are several backdoor paths, all of them leading into 
the main exposure strictly through the unobserved variable History of EMT, which is the 
expression of EMT markers in cancer cells throughout the tumor mass over the entire history of 
the tumor prior to surgery.  All backdoor paths could in theory be blocked by adjusting for 
History of EMT.  Since the variable is unobserved, each backdoor path must be blocked by 
adjusting for other variables along the path. 
 According to the postulated relationships among variables in Figure 8, the minimal set of 
covariates that would need to be adjusted to block all backdoor paths would be age, T-stage 
(tumor size), neoadjuvant treatments (chemotherapy and radiation), N-stage (lymph node 
metastasis), and M-stage (distant metastasis).  Since overall TNM tumor stage is a composite of 
the component T-, N-, and M-stages, tumor stage can be adjusted for as a single variable for 
overall stage rather than as three separate variables for the components.  Confounding due to 
adjuvant treatments is addressed by adjusting for stage.  The variables in the node including 
“Tumor Location,” while associated with patient outcomes, do not appear to influence EMT 
marker expression in cancer cells and therefore need not be included in models. 
 3.6.7. Multivariate time-to-event analysis 
 Adjusted Cox proportional hazards models to control for identified sources of 
confounding included the following independent variables: dichotomous marker expression 
status (marker-positive/marker-negative), age (continuous), overall tumor stage 
(local/regional/distant), neoadjuvant chemotherapy (yes/no), and neoadjuvant radiation therapy 
(yes/no).  Each model contained only one marker expression variable.  I did not include more 
than one marker expression variable simultaneously because markers were not considered 
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mutual sources of confounding for each other based on our DAG.  As with bivariate models, the 
outcome was time from surgery to death, with administrative censoring at 5 years after surgery. 
 3.6.8. Missing data and multiple imputation 
 Several variables for multivariate modeling had large proportions of missing and/or non-
informative responses.  “Non-informative responses” included responses such as “Don’t Know,” 
“Unknown,” and “No Answer.”  Such non-informative responses were effectively missing data.  
Only subjects with informative responses or values for all model variables could be included in 
models.  Since our sample size of 190 subjects was small, adequate precision was an important 
concern.  Retaining all subjects in multivariate models was essential to preserve the maximum 
possible precision.   
 In the presence of missing data, retaining all subjects required imputation of reasonable 
“guesses” for missing values on variables to be included in multivariate Cox models (60).  Many 
imputation methods based on conventional analytic approaches exist—marginal mean 
imputation, multiple regression, and weighted least squares, among others—but these methods 
tend to underestimate standard errors and overestimate test statistics (60).  I used multiple 
imputation (MI), a method that provides consistent, asymptotically efficient, and asymptotically 
normal estimates, assuming the data are missing at random (60). 
 Briefly, MI involves assigning an imputed value for each missing value for a given 
variable conditional on relevant covariates (the imputation model) and by introducing a random 
component into the imputation process.  The imputation model should be at least as rich as the 
analysis model used subsequently.  Using this approach, a statistical package performing MI will 
assign imputed values for all missing values for every variable being imputed, creating a 
complete dataset.  This was done 100 times to generate 100 complete datasets.  Each of these 
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datasets was then analyzed separately using the desired analysis model—in our case, Cox 
proportional hazards models of time-to-death regressed on dichotomous marker expression 
status, age, stage, and neoadjuvant treatments—to produce 100 point estimates and standard 
errors.  The 100 analysis results were finally combined into a single, stabilized estimate and 
confidence interval.  To perform MI, I used the following procedure for every multivariate Cox 
model that I ran after recoding non-informative responses as missing values: 
 First, PROC MI was used to implement Markov Chain Monte Carlo imputation for 100 
imputed datasets.  The imputation model included the following variables: dichotomous marker 
expression status, age, sex, race, tumor stage, tumor location, tumor grade, whether received 
neoadjuvant chemotherapy, whether received neoadjuvant radiation therapy, time from diagnosis 
to death, time from diagnosis to surgery, and time from surgery to death. 
 Therefore, any missing values for all independent variables and also the dependent 
variable of time from surgery to death were substituted for an imputed value.  Multiple time-to-
event variables were included in the imputation model because, while time from surgery to death 
was the outcome of interest, it was missing for some subjects in the final EMT sample.  In fact, 
time from surgery to death was not a variable collected by CanCORS.  Instead, I derived it from 
two variables that were collected: time from diagnosis to death (or last observation), and time 
from diagnosis to surgery.  The formula for time from surgery to death was (time from diagnosis 
to death or last observation) – (time from diagnosis to surgery), keeping in mind that surgery 
virtually always comes after diagnosis. 
 The dataset had no missing data for time from diagnosis to death (or last observation), but 
had about 14% missing data for time from diagnosis to surgery.  Applying the formula above 
produced about 14% missing data for time from surgery to death.  Therefore, to retain all 
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subjects, imputation had to be performed for the dependent variable as well as independent 
variables.  Of note, there was no association between having a missing value for time from 
surgery to death and whether a subject died during the observation period (chi square p-
value=0.3). 
 Second, after creating 100 imputed datasets, I used PROC PHREG to carry out the Cox 
analysis model on each imputed dataset, producing 100 point estimates and standard errors.  The 
analysis model used time from surgery to death as the dependent variable and, for the 
independent variables, included dichotomous marker expression status, age, tumor stage, receipt 
of neoadjuvant chemotherapy, and receipt of neoadjuvant radiation therapy. 
 Third and finally, PROC MIANALYZE was used to combine the 100 point estimates and 
standard errors into a single, stabilized point estimate and 95% confidence interval that retained 
all 190 subjects. 
 3.7. Statistical analysis for latent class analysis 
 3.7.1. Overview 
 The time-to-event analysis addressed the basic question of whether expression levels of a 
given marker were associated with patient outcomes, especially independent of tumor stage.  The 
answer to that question does not, however, provide all of the information we would want to know 
about the marker in terms of its diagnostic usefulness.  We would also want a measurement of 
the diagnostic validity or accuracy of the marker (58).  The basic measures of such accuracy are 
sensitivity and specificity, and estimating these quantities in an appropriate fashion for EMT 
markers was the aim of my latent class analysis. 
 Sensitivity and specificity are defined in terms of both a dichotomous diagnostic test and 
a dichotomous outcome or health state (58).  The clinical use of EMT markers fits comfortably 
 
 
50 
 
within this framework.  Binary EMT marker expression status—marker-positive versus marker-
negative—is easily defined, even if EMT marker expression measurements are initially 
continuous.  The decision that an oncologist faces and that an EMT marker would inform is 
inherently binary: at the time of diagnosis, and given that a primary tumor has been found, does 
the patient likely have or not have metastatic disease? 
 Traditional, straightforward calculations of sensitivity and specificity are based on a 
cross-tabulation of patient classification according to the new or “test” diagnostic and patient 
classification according to a gold standard measure of the health state of interest (58).  A gold 
standard measure has perfect (or nearly perfect) accuracy in correctly classifying both those with 
and without the health state of interest, which in this case is presence or absence of metastatic 
disease.  The standard measures of presence or absence of metastatic disease are lymph node 
evaluation (LN) and radiologic imaging (RI).   
 Empirically, it is clear that these measures, either individually or taken together, are not 
sufficiently accurate to be considered a gold standard.  Specifically, about 25% of CRC patients 
found to have local disease according to these diagnostics ultimately experience disease 
recurrence (4).  Such patients likely had metastatic disease at the time of diagnosis that was not 
successfully detected by LN or RI.  Since about 40% of CRC patients are diagnosed as having 
local disease, this suggests that approximately 10% of all CRC patients—about 14,000 people 
nationwide each year—have metastatic disease at the time of diagnosis that the two conventional 
diagnostics jointly fail to detect (8, 10). 
 The failure of LN and RI to constitute a gold standard measure implies that EMT marker 
sensitivity and specificity cannot be estimated by simple calculations based on a cross-tabulation.  
However, it is possible to estimate the sensitivity and specificity from statistical models that do 
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not require the assumption that any member of a panel of diagnostic tests counts as a gold 
standard.  Latent class models are precisely suited for this purpose (61).  We used latent class 
analysis (LCA) to estimate the sensitivity and specificity of EMT markers to assess cancer cell 
detachment from primary tumors while accounting for the sensitivity and specificity of LN and 
RI to do the same, but without assuming that any of the diagnostics constituted a gold standard. 
 3.7.2. Latent class framework 
 Latent class models are a subset of latent variable models, which attempt to identify 
subgroups within a population by postulating that the subgroups represent different levels of an 
unobserved, error-free latent variable (62).  The latent variable is measured indirectly by multiple 
observed indicator variables (also called manifest variables), each of which is conceived as being 
determined by its own error term and the latent variable.  Individuals’ response patterns to the 
indicators can be used to estimate two kinds of parameters: the prevalence of each latent 
subgroup (gamma parameters or class-membership probabilities) and, within each latent 
subgroup, the probability of a given response to each indicator (rho parameters or item-response 
probabilities).  Latent class models are latent variable models that use categorical indicators and 
postulate a categorical latent variable.  Figure 9 depicts a generic latent class model with three 
manifest variables. 
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Figure 9. Generic latent class model with three indicator variables (based on Collins and Lanza, 
2010) (62) 
 
 
 
 
 
 
 
 
 
 
 In a valid latent class model, the indicators are related to each other through the latent 
variable but are otherwise independent of one another (62).  This is known as the local 
independence assumption.  It implies that the error terms of the indicators are not associated or 
correlated with each other.  A further implication is that, within any single (unobserved) latent 
class, the indicator variables are independent of each other.  In fact, this conditioning on latent 
class is what the “local” in “local independence assumption” refers to. 
 3.7.3. Latent class model for diagnostics of cancer cell detachment from primary  
           tumors 
 
 Figure 10 depicts my conceptual model of the relationship between cancer cell 
detachment from the primary tumor and the diagnostic tests to assess it.  Detachment is the latent 
variable, that is, the phenomenon of interest that is not observed directly.  EMT markers, LN, 
and RI are the indicators. 
 
Latent Variable (error-free, unobserved) 
Indicator Variable 1 
(observed)  
Indicator Variable 2 
(observed) 
Indicator Variable 3 
(observed) 
Error1 Error2 Error3 
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Figure 10. Latent class model of diagnostic tests to evaluate cancer cell detachment from primary 
tumors 
 
 
 
 
 
 
 
 
 
 
 
 3.7.4. Data used for latent class analysis 
 Based on the results of the time-to-event analysis, only E-cadherin expression as a 
weighted average of tumor cores was associated with time-to-death.  Therefore, EMT status in 
the LCA was defined solely in terms of E-cadherin weighted average expression.  The LCA was 
limited to the 188 subjects in the EMT study sample with E-cadherin weighted average 
measurements, as 2 of the 190 subjects did not have E-cadherin measurements.  
  The only data input into LCA models were the three diagnostic tests of cancer cell 
detachment.  The sensitivity and specificity of each diagnostic could be estimated freely or set to 
fixed values.  Free estimation requires observed data for that particular diagnostic, while a fixed 
value does not.  All diagnostics were treated as binary test-positive versus test-negative.  Test-
positive meant evidence supporting cancer cell detachment from the primary tumor while test-
negative meant evidence supporting lack of cancer cell detachment. 
 
  
Cancer cell detachment from primary tumor (unobserved) 
EMT marker levels in cancer 
cells in primary tumor 
(observed) 
Radiologic imaging 
results         
(observed) 
Lymph node 
evaluation results 
(observed) 
Error1 Error2 Error3 
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EMT 
 In the time-to-event analysis, we identified three different cut points along the continuum 
of observed E-cadherin weighted average expression that provided informative relationships 
between dichotomous marker expression and patient outcomes.  On the average intensity scale of 
0-3, these were 0.52, 0.60, and 0.85.  In the LCA we examined how sensitivity and specificity 
varied with cut point.  For any given cut point, EMT-positive status meant low E-cadherin 
expression (below the cut point) and EMT-negative status meant high E-cadherin expression (at 
or above the cut point).  EMT sensitivity and specificity were both freely estimated in all latent 
class models. 
 Lymph Node Evaluation and Radiologic Imaging 
 Freely estimating all possible sensitivity and specificity parameters in a setting with only 
three binary diagnostics leads to poor model specification (see Analysis section below).  To cope 
with this, in each model I fixed (i.e. set or restricted) some of the values of LN and RI sensitivity 
and specificity while freely estimating the others as well as EMT sensitivity and specificity.  This 
approach required both observed LN and RI test results for freely estimated parameters and also 
determination of fixed values for restricted parameters. 
 Observed LN and RI results were not available in CanCORS.  As an approximation, I 
inferred them from subject tumor stage using the rules presented in Table 2.  These inferred test 
results were used for freely estimated LN and RI sensitivity and specificity parameters. 
 For LN and RI parameters assigned fixed values in a given model, a value of 60% or 80% 
was assigned for each restricted sensitivity parameter and a value of 90% or 100% was assigned 
for each restricted specificity parameter.  These values were chosen to represent bounds to assess 
the influence on model results of different combinations of assumptions about high or low 
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diagnostic accuracy for RI and LN.  We varied the combinations of fixed values and of which 
LN and RI parameters were restricted across models to observe how doing so impacted the EMT 
estimates. 
 The choice of 60% to represent poor sensitivity and 80% to represent good sensitivity 
was based in part on the fact that about 25% of colorectal cancer patients diagnosed with local 
disease experience recurrence after surgery (4).  In addition, roughly 40% of colorectal cancer 
patients are currently diagnosed with local disease (63).  Together, these facts suggest that the 
“double false negative” proportion for LN and RI is about 10% of all colorectal cancer patients. 
 
Table 2. Rules for inferring lymph node and radiologic imaging test results from tumor stage 
Tumor Stage Diagnosis Lymph Node Assignment Imaging Assignment 
Local Negative Negative 
Regional Positive Negative 
Distant Based on diagnosed N-stagea Positive 
aFor 23 subjects diagnosed with distant disease, lymph node status was assigned as lymph node-
negative if N0 (n=3) and as lymph node-positive if N1 or N2 (n=11).  Nine subjects with 
unknown N-stage were assigned as lymph node-positive. 
 
 For metastatic disease, false negative results are more clinically serious than false 
positive results.  However, the problem is not testing falsely negative for either LN or RI, but 
testing falsely negative for both.  The false negative proportion for a single diagnostic is equal to 
(100 – sensitivity)% (58).  Thus, a test with sensitivity of 60% or 80% will have a false negative 
proportion of 40% or 20%, respectively.   
 Assuming that LN and RI test results are conditionally-independent events, the double 
false negative proportion is the product of the false negative proportions for each of the two tests.  
Both tests having sensitivity of 80% yields a double false negative proportion of 4%.  If both 
tests have sensitivity of 60%, then the double false negative proportion is 16%.  If one test has 
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sensitivity of 60% and the other has sensitivity of 80%, then the double false negative proportion 
is 8%. 
 I chose 60% and 80% as values representing low and high test sensitivity, respectively, 
because when either LN or RI has low sensitivity and the other has high sensitivity, the assumed 
double false negative proportion of 8% is close to the observed estimate of 10%.  In addition, 
when both tests are set to high sensitivity or both set to low sensitivity, the resulting double false 
negative proportions of 4% and 16% set up reasonable extreme bounds around the observed 
estimate. 
 Specificity bounds of 90% and 100% were chosen because I assume that the specificities 
of both LN and RI are close to perfect.  To get a false positive result for either of these tests, the 
radiologist or pathologist would have to believe that he is looking at cancer cells in a scan or 
under the microscope when in fact he is not.  This might occur occasionally but I assume it is 
relatively rare. 
 Whether freely estimated or restricted, every LN and RI sensitivity and specificity 
parameter represented a binary diagnostic test.  LN-positive would mean that cancer cells were 
found in lymph nodes near the primary tumor and LN-negative that no cancer cells were found 
there.  RI-positive would indicate detection of a distant metastasis via imaging and RI-negative 
would indicate no such detection of distant metastasis. 
 3.7.5. Analysis 
 All models included all three diagnostic tests.  In every case, I sought a 2-class solution 
distinguishing high risk from low risk for metastatic disease. 
 A properly specified latent class model has a positive number of degrees of freedom (df), 
given by df = W – P – 1, where W is the number of possible response patterns and P is the 
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number of parameters estimated (62).  Three binary indicators yield 23 = 8 possible response 
patterns.  When all class-membership and item-response parameters are freely estimated, a 2-
class model with 3 indicators estimates 7 parameters (1 class-membership and 6 item-response), 
leaving 8 - 7 - 1 = 0 df.  Using fixed sensitivity or specificity values for LN and RI reduced the 
number of parameters estimated in a given model, thereby giving positive degrees of freedom. 
 I ran separate models using each of the different E-cadherin cut point values mentioned 
earlier—about 0.52, 0.60, and 0.85—to create the EMT indicator to assess the impact of E-
cadherin cut point on the sensitivity and specificity of the resulting indicator.  The fixed values 
assigned for LN and RI sensitivity or specificity were also varied across models.  I used PROC 
LCA in SAS for the latent class analyses (64).  The SAS procedure used an iterative expectation-
maximization algorithm to obtain maximum likelihood estimates for freely-estimated 
parameters. 
 3.8. Ethical considerations 
 3.8.1. IRB approval 
 The dissertation proposal was defended on 16 April 2013.  On 23 April 2013, an 
application for approval of the project was submitted to the UNC Institutional Review Board 
(IRB).  The project was assigned IRB Study #13-1897.  On 25 April 2013, the IRB notified us 
that the project was approved.  No implementation activities were undertaken until IRB approval 
was received.  The IRB granted one-year extensions on 24 February 2014 and 14 January 2015, 
covering the entire period from just after the proposal through graduation from the PhD program. 
 3.8.2. Informed consent  
 Subjects consented to participate in the study and provide tumor specimens at the time of 
enrollment in 2003-06.  While they did not specifically consent to have their tumor specimens 
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used to study EMT markers, they did consent to the tissue samples being used for biomarker 
research generally.  Thus, the original consent covered all dissertation project activities, and 
therefore subjects did not need to be sought out and re-consented to carry out the project. 
 3.8.3. Potential risks to subjects 
 The only risk this research posed to subjects was possible breach of confidentiality in the 
event that data security was compromised.  Subject data used in the project were deidentified and 
never linked to the CanCORS key of subject identifiers.  Further, all analyses were carried out on 
a password-protected computer used only by the candidate.  To the best of our knowledge, data 
security was never breached.  Even if it was breached without our knowledge, it appeared 
unlikely that subject confidentiality could be compromised even then since the data were 
deidentified. 
 3.8.4. Potential benefits to subjects 
 There were no direct benefits of this research to participating subjects.  While the 
knowledge gained could benefit future CRC patients, the work was performed long after the 
knowledge could have been beneficial to those enrolled. 
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CHAPTER 4. MARKERS OF EPITHELIAL-MESENCHYMAL TRANSITION AND 
MORTALITY IN A POPULATION-BASED PROSPECTIVE COHORT OF 
COLORECTAL CANCER PATIENTS 
 
 4.1. Introduction 
 Epithelial-mesenchymal transition (EMT) is widely considered an important mechanism 
of cancer cell metastasis (2, 65, 66).  It connects epithelial cells to metastasis, which account for 
roughly 80% of cancer and 90% of cancer deaths, respectively (1).  EMT markers measured in 
primary-tumor cancer cells are potentially useful diagnostic tools to assess patient risk of 
metastatic disease and guide treatment decisions, even when metastases are not detected by 
lymph-node evaluation or radiologic imaging. 
 The EMT mechanism involves epithelial cells temporarily becoming mesenchymal cells 
(2).  This occurs when cellular expression levels of EMT inducers increase, leading to decreased 
expression of epithelial markers and increased expression of mesenchymal markers.  These 
changes are manifest as loss of adhesion to adjacent cells that enables detachment of the 
transitioning cell from the primary tumor, as well as cytoskeletal and other modifications that 
enhance motility and invasiveness. 
 Past studies of associations between EMT markers in primary tumors and patient 
outcomes have measured marker expression in different ways and often performed statistical 
analyses that were not as informative as possible (5).  For example, previous studies have used 
single-hospital samples that typically are not representative of a well-defined population.  
Different studies of the same marker measured using the same laboratory technique often used 
different scoring scales and defined marker-positive versus marker-negative status in different 
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ways.  The lack of uniform methods across studies could contribute to inconsistent findings and 
hamper translation of EMT markers to clinical use. 
 Selecting markers based on our previous literature review (5), we measured the EMT 
inducer Snail, epithelial marker E-cadherin, and mesenchymal marker Integrin beta-6 in primary 
tumors from a population-based prospective cohort study of colorectal cancer (CRC) mortality 
and estimated their associations with time-to-death.  We hypothesized that low expression of E-
cadherin, and high expression of Snail and Integrin beta-6, would be associated with shorter 
times from surgery to death compared to opposite expression levels.  We also introduce methods 
that might help to improve standardization of measurements and analyses across studies. 
 4.2. Methods 
 4.2.1. Study population 
 Subjects were enrolled in the Cancer Care Outcomes Research and Surveillance 
Consortium (CanCORS), a population-based, prospective, case-only, multi-site observational 
study of colorectal and lung cancer patients (48).  Briefly, the study assessed the impact of 
health-system, provider, and patient factors on cancer outcomes.  Patients were at least 21 years 
of age at diagnosis and were enrolled within 3 months of diagnosis during 2003-06.  The study 
collected patient surveys, surrogate surveys for patients who were deceased or too ill to 
participate, and medical records data.  Vital status for all subjects was verified using the Social 
Security Death Index on 4 May 2010, providing at least 42 months of follow-up observation per 
individual. 
 Medical records abstractors at each site collected information on tumor characteristics 
and cancer treatments.  Patient and, when necessary, surrogate surveys were completed using 
computer-assisted telephone interviews that queried demographic and socioeconomic factors 
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(age, insurance coverage, income), as well as treatment preferences and interactions with 
providers (67). 
 The North Carolina CanCORS site was the only one to collect tumor specimens.  It 
enrolled 990 CRC patients but no lung cancer patients.  Subjects in the present biomarker study 
came from a catchment area of 33 counties in eastern and central North Carolina at the time of 
diagnosis.  Investigators obtained primary tumor and normal adjacent colorectal tissue samples 
from 506 subjects.  
 Formalin-fixed, paraffin-embedded tissue specimens were sent from hospitals across the 
catchment area to the University of North Carolina at Chapel Hill (UNC), where they were used 
to construct tissue microarrays (TMAs) as described previously (50).  Most subjects had multiple 
cores from both primary tumor and normal margin.   For this analysis, we measured EMT 
markers in 12 representative TMAs that included specimens from 219 subjects.  To be included 
in the study sample, subjects had to have at least one core of tumor tissue successfully stained for 
one marker, with that core having at least 50 epithelial cells and unambiguous histology.  From 
the 12 TMAs, we excluded 26 subjects lacking adequate tumor tissue and an additional 3 
subjects who could not be linked to medical records data, yielding a final study sample of 190 
subjects. 
 4.2.2. Immunohistochemistry 
 We selected EMT markers for evaluation based on the results of previous studies and 
criteria discussed in our prior literature review (5).  Marker protein expression was measured 
using the following antibodies: E-cadherin (mouse monoclonal ready to use [RTU], clone 36B5 
[cat #PA0387] from Leica Microsystems Inc. [Norwell, MA]), Integrin beta-6 (goat polyclonal 
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[sc-6632] from Santa Cruz Biotechnology [Dallas, Texas]), and Snail (goat polyclonal [ab53519] 
from Abcam [Cambridge, MA]). 
 Immunohistochemistry (IHC) was performed at the UNC Translational Pathology 
Laboratory (TPL) using the Bond fully-automated slide staining system (Leica Microsystems 
Inc., Norwell, MA).  Slides were deparaffinized in Bond Dewax solution (AR9222) and hydrated 
in Bond Wash solution (AR9590). Antigen retrieval was performed at 100C for Integrin beta-6 
and Snail (for 20 minutes or 30 minutes, respectively) in Bond-epitope retrieval solution 1 at pH 
6.0 (AR9961) and for E-cadherin for 20 minutes at 100C in solution 2 at pH 9.0 (AR9640).  
After pretreatment, anti-E-cadherin was applied for 15 minutes, anti-Snail (1:200) for 30 minutes 
and anti-Integrin beta-6 (1:100) was applied for 1 hour. 
 Detection of Snail and Integrin beta-6 was performed using the Bond Intense R Detection 
System (DS9263) supplemented with the LSAB+ kit (DAKO, Carpinteria, CA).  E-cadherin 
detection used the Bond Polymer Refine Detection System (DS9800).  Stained slides were 
dehydrated and cover-slipped.  Positive and negative controls (no primary antibody) were 
included for each antibody.  All assays were single-marker (i.e. no multiplex assays). 
 Stained slides were digitally imaged at 20× magnification using the Aperio ScanScope 
XT (Aperio Technologies, Vista, CA).  Digital images were stored in the Aperio Spectrum 
Database.  Example images of staining and annotations are provided in Figures 4-6. 
 4.2.3. Automated analysis of digital IHC images 
 Computer algorithms annotated and scored every eligible tissue core to obtain continuous 
marker expression data.  We used approximately 65 cores originating from two TMAs for 
algorithm training and automated-analysis validation.   
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 Definiens Composer Technology (Tissue Studio version 2.1.1 with Tissue Studio Library 
version 3.6.1; Definiens Inc., Carlsbad CA) was used to identify regions enriched in epithelial 
cells in IHC-stained TMA cores.  To detect differences in cell shape and tissue structure, we 
developed two Composer algorithms per marker—one for cores containing normal adjacent 
tissue and a second for tumor cores—as both types of tissue were present on each TMA.   
 After Composer training, we developed two Tissue Studio scoring algorithms 
(“solutions”) per marker.  Different Composers were used to identify epithelial cell regions but 
identical settings were used to determine relative DAB staining intensity.  The 
Composer_MarkerArea Solution was used to detect E-cadherin staining.  This algorithm gave 
average intensity readings for each core on a continuous scale of 0-3 and included both 
membrane and cytoplasmic E-cadherin staining.   Integrin beta-6 membrane staining was 
detected using the Composer_Nuclei_Membranes&Cells Solution.  We used the 
Composer_Nuclei(Positive_vs_Negative) Solution to detect nuclear Snail expression.  Integrin 
beta-6 and Snail were measured as core percent positive cells (Integrin) or nuclei (Snail) on a 
continuous scale of 0-100. 
 To evaluate the reliability of computer annotations, one of us (ELB) used Aperio 
ImageScope (version 11.2; Leica Biosystem, Buffalo Grove, IL) to manually annotate the same 
65 cores per marker that were used to optimize Tissue Studio solutions.  He remained blind to 
patient and tumor characteristics while annotating.  The manually-annotated cores—considered 
the gold standard for digital separation of tissue types—were then analyzed using appropriate 
Aperio scoring algorithms (Membrane v9 algorithm for E-cadherin and Integrin beta-6, Nuclear 
v9 algorithm for Snail). Automated scores obtained via manual and automated annotation 
produced Pearson correlations of 0.91 for E-cadherin, 0.88 for Integrin beta-6, and 0.94 for Snail.  
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Having verified the accuracy of the annotation algorithms for the three markers, all 12 TMAs 
stained for E-cadherin, Integrin beta-6 and Snail were analyzed (36 slides in total). 
 Subjects typically had multiple cores available of a given tissue type (tumor or normal).  
To assign an expression value for each subject by marker and tissue type, we handled replicate 
cores in two ways: first, as a weighted average of cores, and second, by assigning the expression 
value of the subject’s “worst” core as the marker expression value.  For weighted averages, the 
weights were area analyzed for E-cadherin, number of cells for Integrin beta-6, and number of 
nuclei for Snail.  The worst score by tissue type was assigned as the lowest core average intensity 
for E-cadherin, as the highest core percent positive cells for Integrin beta-6, and as the highest 
core percent positive nuclei for Snail. 
 After observing unexpected results when comparing mean Snail expression in tumor 
tissue to normal tissue, we trained two additional Snail scoring algorithms on a different TMA 
than the one used to develop the original scoring algorithms: a second nuclear algorithm and a 
whole-cell algorithm that scored Snail expression in any part of a cell.  These additional Snail 
scoring algorithms measured expression on a continuous percent positive scale and were applied 
to all 12 TMAs.  The results of the two additional Snail algorithms were qualitatively similar to 
those from the original nuclear algorithm.  Thus, for analysis we used only Snail expression 
values based on the original algorithm. 
 4.2.4. Outcome 
 In statistical models, the dependent variable was length of time in days from primary 
tumor surgery until all-cause mortality, with administrative censoring at 5 years after surgery. 
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4.2.5. Covariates 
 Covariates for multivariate statistical models were selected based on prior studies (5), 
considerations of biological plausibility, and directed acyclic graph theory (59). 
 We adjusted for age, neoadjuvant chemotherapy, neoadjuvant radiation therapy, tumor 
size (T-stage), lymph-node metastasis diagnosis (N-stage), and distant metastasis diagnosis (M-
stage).  We adjusted for overall TNM stage as a single variable instead of adjusting for the 
component stages as three separate variables since including both overall stage and any of the 
component stages would constitute inappropriate overadjustment.  Because we adjusted for 
stage, cancer treatments prior to surgery were included as covariates but we excluded cancer 
treatments occurring after surgery. 
 Age was modeled as a continuous variable.  We categorized stage (local/regional/distant), 
neoadjuvant chemotherapy (yes/no), and neoadjuvant radiation (yes/no). 
 4.2.6. Marker expression cut point optimization 
 Our data collection yielded six continuous marker expression variables: weighted average 
and worst score for each of Snail, E-cadherin, and Integrin beta-6.  For each variable, we wished 
to identify the cut point distinguishing marker-positive status from marker-negative that was 
most strongly associated with time-to-death. 
 For every possible cut point along any marker expression continuum, we defined marker-
positive status as expression at or above the cut point and marker-negative status as expression 
below the cut point.  Thus, marker-positive always meant high expression and marker-negative 
always meant low expression.  Whether marker-positive status is clinically desirable depends on 
the particular marker.  E-cadherin-positive status would be expected to correlate with better 
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outcomes (i.e. longer time-to-death) (2, 5, 56), whereas Snail-positive (2, 5) or Integrin beta-6-
positive (23) status would be expected to correlate with worse outcomes.  
 To identify the statistically-optimal cut point for each continuous marker expression 
variable, we used a SAS macro to assess the model goodness of fit for a series of bivariate 
associations between dichotomous marker expression status and time-to-death.  The macro 
iteratively dichotomized marker expression at every possible cut point in the observed tumor 
tissue data, with each cut point corresponding to a different subject’s expression value. Each 
dichotomization of marker expression status was fit as the only independent variable in a Cox 
model with time-to-death as the outcome, producing a model fit statistic.  The expression value 
with the lowest model fit statistic was considered the statistically-optimal cut point. 
 For macro SAS code and further details, including comparison of this approach to 
receiver operating characteristic curves, see Appendix B. 
 4.2.7. Statistical analysis 
 We first used unpaired two-sample t-tests to assess whether average continuous marker 
expression differed between tumor and normal tissue.  All subsequent analyses used tumor tissue 
only.  We applied the macro to the tumor tissue data for the six marker expression variables to 
identify the statistically-optimal cut point for each.  Every optimal cut point was used to create a 
dichotomous marker expression variable (positive/negative). 
 We generated Kaplan-Meier survival curves stratified by dichotomous marker expression 
status for one marker or two markers jointly, assessing differences between strata using the 
logrank test.  Next, for each optimally-dichotomous marker expression variable, we fit 
unadjusted and adjusted Cox proportional hazards models of time-to-death.  Prior to modeling, 
non-informative observations (e.g. “No Answer,” “Don’t Know,” “Unknown”) were recoded as 
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missing.  Missing data for all model variables were evaluated using multiple imputation.  P-
values of 0.05 or below were considered statistically significant.  All analyses were performed 
using SAS 9.3 (SAS Institute, Cary, NC). 
 The Institutional Review Board at UNC approved the protocol.  All subjects provided 
informed consent. 
 4.3. Results 
 Comparison of subject characteristics for overall North Carolina CanCORS and the 
subset for whom EMT markers were measured in primary tumors suggests that the EMT study 
sample remains representative of the source population (Table 3). 
 On average, tumor tissue had lower E-cadherin expression and greater Integrin beta-6 
expression than normal adjacent tissue regardless of whether expression values were assigned as 
a weighted average of cores or as the worst core (Table 4).  However, average Snail expression 
was higher in normal tissue than in tumor tissue.  While the difference was not large, this 
relationship was consistent across both ways of assigning expression values and all three Snail 
scoring algorithms. 
 On the average intensity scale of 0-3 for E-cadherin, we found that the statistically-
optimal cut point was about 0.52 for weighted averages and 0.42 for worst cores.  On a percent 
positive cells scale for Integrin beta-6, the optimal cut point was about 9.4% for weighted 
averages and 7.7% for worst cores.  On a percent positive nuclei scale for Snail using the first 
nuclear scoring algorithm, the optimal cut point was about 25.2% for weighted averages and 
63.6% for worst cores.  For weighted average and worst core expression for each marker, Table 
5 presents the cross-tabulation of dichotomous marker expression status defined by the 
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statistically-optimal cut point, first, with tumor stage, and second, with the risk of dying within 5 
years of surgery. 
 For E-cadherin weighted averages, subjects with low tumor expression had worse 
survival than those with high tumor expression (Figure 11).  None of the Kaplan-Meier curves 
stratified by the other five optimally-dichotomous marker expression variables revealed a 
statistically-significant difference in survival (Figures 12-16).  We also generated survival curves 
jointly stratified by two dichotomous marker expression variables (Figures 17-22).  While 
several of these produced statistically-significant logrank test results, graphical examination did 
not suggest any clear patterns based on biological expectations or clinical usefulness. 
 Bivariate proportional hazards model results paralleled the single-variable stratified 
survival curves: low E-cadherin weighted average expression was associated with greater 
hazards of dying than high expression (Hazard Ratio [HR] =2.84, 95% Confidence Interval [CI] 
1.29, 6.28), and no associations were found for any of the other optimally-dichotomous 
expression variables (Table 6).  These relationships held in adjusted models: low E-cadherin 
weighted average expression remained strongly “harmful” relative to high expression (HR=2.57, 
95% CI 1.10, 6.03), while no other optimally-dichotomous marker expression variables had an 
effect on time-to-death. 
 We explored several trade-offs between strength of cut-point/time-to-death association 
and the number of subjects whose treatments might change due to clinical use of EMT markers.  
Specifically, we considered three different E-cadherin weighted average cut points that were 
either statistically significant or nearly so: about 0.52 (statistically-optimal value), 0.60, and 0.85 
(Table 7).  Setting the cut point to a value other than the statistically-optimal value led to hazard 
ratio point estimates that were weaker than the one at the optimal cut point, but marker 
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expression status was still effectively associated with outcomes at each of these cut points.  
Notably, the precision of hazard ratio estimates was better at cut points other than the 
statistically-optimal value.   
 The number of subjects whose treatments might change based on E-cadherin 
measurements—those diagnosed with local disease who are E-cadherin-negative—varied 
substantially with cut point.  Of 99 subjects with E-cadherin measurements and diagnosed with 
local disease, 6 were E-cadherin-negative at the optimal cut point, 16 at a cut point of 0.60, and 
56 at a cut point of 0.85. 
 4.4. Discussion 
 EMT markers can link epithelial cancer cells in primary tumors to risk for metastatic 
disease.  We found that, when measured as a weighted average of tumor cores, E-cadherin 
expression in colorectal cancer cases was associated with mortality independent of stage.  By 
identifying possible metastatic disease that might be undetected by radiologic imaging or lymph-
node evaluation, measurement of E-cadherin or other EMT markers in primary tumor cancer 
cells has the potential to alter the treatment and outcomes of cancer patients. 
 An EMT marker must overcome at least two hurdles to become a useful diagnostic tool.  
First, expression levels measured in cancer cells from resected primary tumors must be 
associated with the length of time from surgery to death, independently of other relevant clinical 
factors.  Second, the most clinically-useful definition of marker expression status must be 
determined.  Though related, these issues are not identical: the first is statistical and the second 
practical.  They differ because marker expression is inherently continuous, while treatment 
decisions are binary and therefore imply cut points.  Many cut points along a continuum could 
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yield significant associations with time-to-death.  Deciding which one to use clinically is not a 
matter of best model fit alone. 
 E-cadherin has been the most-studied EMT marker in prior reports (5, 56).  Among 
hospital-based samples that examined survival stratified by E-cadherin expression status, four 
found that reduced E-cadherin was associated with worse outcomes (24, 29, 43, 68).  Four 
studies found that E-cadherin expression by itself was not associated with survival (16, 69-71).  
In terms of multivariate modeling of overall survival, one study found that E-cadherin was an 
independent prognostic marker (43) while three concluded that it was not (29, 68, 70). 
 To our knowledge, there has been only one previous population-based study that 
measured E-cadherin in CRC primary tumor cancer cells and estimated its association with 
patient outcomes (72).  The study assigned each specimen a separate score for membrane and 
cytosolic staining.  They found no evidence that membrane staining was associated with either 
overall survival or time-to-recurrence.  Cytosolic staining was associated with time-to-recurrence 
but not overall survival. 
 A meta-analysis concluded that reduced E-cadherin expression was associated with worse 
CRC outcomes (56).  This summary must be interpreted with caution because it combined results 
from studies with very different definitions of E-cadherin positive/negative status.  We have 
argued elsewhere that combining studies in this fashion is not valid (5).  Nevertheless, the 
summary suggests that, given conflicting findings when comparing individual studies of the 
prognostic value of E-cadherin, overall the evidence supports its utility.  Past studies do not, 
however, provide much clarity in deciding the best way to measure E-cadherin or what cut point 
to use for clinical purposes. 
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 Our study supports the use of E-cadherin as an independent prognostic marker of CRC 
patient outcomes, at least when measured as a weighted average of tumor cores.  While the 
marker had no effect on time-to-death when measured as worst (i.e. lowest) core expression, the 
weighted average is more representative of the tumor’s overall E-cadherin status because it 
incorporates measurements from at least as many cells as the worst core.  Notably, the 
association between dichotomous E-cadherin weighted average status and outcomes was 
independent of TNM stage.  This suggests that the marker provides prognostic information 
beyond what is captured by tumor size, lymph-node evaluation, and radiologic imaging. 
 Our results can only be directly compared to other studies using the same data collection 
and analysis procedures in terms of type of data collected (continuous or ordinal), marker 
expression scale (for continuous data: average intensity, percent positive, or H scores), and cut 
point and covariate selection.  At present, no such direct comparison with another study is 
possible.   
 Most prior studies that measured continuous E-cadherin data did so on the percent 
positive scale.  We encourage future investigators to adopt our use of the average intensity scale 
for E-cadherin, for two reasons.  First, the average intensity scale imposes fewer assumptions on 
the data than the percent-positive and H-score scales.  Second, at the level of the individual cell, 
the percent-positive and H-score scales assign coarser expression measurements than average 
intensity.  Altogether, these arguments suggest that the average intensity scale provides the 
richest, most-informative continuous scale on which to measure E-cadherin. 
 On the average intensity scale, we found that Integrin beta-6 and Snail had much lower 
expression than E-cadherin, with a high proportion of cores having expression values below the 
threshold for background staining (Figure 4).  Therefore, we suggest that the percent positive 
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scale is appropriate for EMT inducers and mesenchymal markers, and would reserve the average 
intensity scale for epithelial markers. 
 Clinical implementation of an E-cadherin assay based on a continuous average intensity 
scale would require automated analysis of IHC slide images.  Standardized controls with known 
E-cadherin staining intensities would have to be included with each run to ensure proper staining 
and analysis calibration.  However, it would be possible to establish such an assay since whole-
slide imaging for diagnostic purposes is widely used for the evaluation of estrogen receptor, 
progesterone receptor and HER2/Neu IHC stains.  The College of American Pathologists 
recently released guidelines for validating new digital analysis assays for diagnostic use (73). 
 For Integrin beta-6, to our knowledge only one previous study has examined its 
prognostic role in CRC (23).  The study reported that high expression was associated with worse 
survival, especially among Stages I and II patients.  It found that Integrin beta-6 was an 
independent prognostic marker in a multivariate Cox model.  These results matched what one 
would expect for this mesenchymal marker. 
 We found no evidence that Integrin beta-6 expression was associated with survival or 
could serve as an independent prognostic marker.  Numerous differences in design and analysis 
could have contributed to the discrepancy between the first study and ours.  The earlier study 
used manual IHC scoring, a different antibody, had a larger sample size (n=488), and used a 
different outcome for analysis (disease-related deaths compared to our use of all-cause 
mortality). 
 Our Integrin beta-6 estimates have poor precision, particularly for worst cores.  It is 
possible that the particular antibody we used had nonspecific staining, which would be a problem 
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with the antibody rather than the marker.  We encourage further work on Integrin beta-6 to 
resolve the inconsistent findings between studies. 
 For Snail, previous studies had highly conflicting results.  Two studies found that 
elevated expression was associated with worse survival than low Snail expression (37, 70) while 
two reported no difference in survival by Snail expression status (71, 74).  In multivariate time-
to-death modeling, one paper reported an effect of Snail expression status on outcomes (70) and 
another found no effect (74). 
 We found no evidence that Snail expression status was associated with survival or was an 
independent prognostic marker.  Indeed, in our study Snail failed to meet minimal expectations 
based on the EMT mechanism when normal tissue exhibited greater average expression than 
tumor tissue.  Unlike Integrin beta-6, for which there is only one prior study, our finding of lack 
of association between Snail and outcomes can be compared to inconsistent findings across 
several previous studies.  Although the lack of association in our study might be due to 
nonspecific staining as could be the case with Integrin beta-6, taken together, prior and present 
results suggest that Snail would not be a useful clinical marker for CRC. 
 Our study had a number of important strengths.  First, it used tumor specimens from a 
population-based prospective observational study.  This gives our results greater external validity 
than the hospital-based samples typically used in studies of EMT markers and patient outcomes 
(75).  The only previous population-based study of this topic in CRC used tumor specimens from 
a single hospital that served virtually every CRC case in a defined geographic region (72).  As 
far as we know, ours is the first study of EMT markers and CRC outcomes that collected tumor 
specimens from multiple clinics, with all of the variation in specimen handling and transport that 
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implies.  This makes our finding that E-cadherin expression was associated with CRC outcomes 
particularly striking. 
 Another strength is our approach to cut point determination.  After collecting continuous 
marker expression data, for each expression variable we performed an exhaustive automated 
search along the continuum for the cut point that yielded the largest difference by model fit 
between the hazard functions (i.e. survival experiences) of marker-positive and marker-negative 
subjects.  Most studies have only examined a small number of possible cut points, often because 
they collected ordinal data but even when they collected continuous data.  In addition, cut point 
decisions have typically been arbitrary, often using convenient percentiles or subjective 
judgments about high versus low staining.  In contrast, our approach fully exploits the richness 
of continuous data, and identifies a cut point based on an objective criterion (best model fit) 
applied to an examination of how marker expression relates to the outcome of interest in the 
observed data. 
 Notably, of our six continuous marker expression variables, the optimal cut point of only 
one (E-cadherin weighted average) yielded an association with time-to-death.  For a given 
continuum, the optimization macro identifies the observed cut point with the best model fit 
compared to all of the other observed cut points, but this does not guarantee that the statistically-
optimal cut point will be associated with outcomes.  This suggests that the optimization 
technique is ideal for evaluating associations between cancer biomarkers and patient outcomes.  
If the marker is associated with outcomes, it will find the strongest statistical association that 
exists in the data.  If the marker is not associated with outcomes, the exhaustiveness of the 
procedure provides especially strong evidence that no association could be detected. 
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 Finally, to promote standardization across studies, we selected our modeling adjustment 
variables based on the results of past studies and an appropriate conceptual framework of 
directed acyclic graph theory.  Estimates of the effect of marker expression on time-to-death are 
only comparable across studies if the studies adjusted for the same set of covariates, preferably 
with the same variable coding.  Thus, it is important that researchers working on studies of EMT 
markers and patient outcomes standardize their covariate adjustment sets across investigative 
teams. 
 Several limitations must be noted.  Our study did not sample tumors in a consistent way.  
Ideally, each tumor would have been sampled at the invasive front, tumor center, and an edge of 
the tumor away from the invasive front.  However, for any given tumor in our dataset, we do not 
know from which part of the tumor our tissue specimens came.  EMT marker expression could 
vary throughout a tumor and it may be that, for clinical purposes, physicians should always 
sample a particular portion (e.g. the invasive front).  Not knowing from which part of the tumor 
each core came, we could not calculate portion-specific estimates of, say, the association 
between invasive front E-cadherin and time-to-death, and separately, the association between 
tumor center E-cadherin and time-to-death. 
 A second limitation is that our outcome in statistical models was time to all-cause 
mortality.  This may have led to weaker associations than would have been observed with an 
outcome of time to cancer-specific mortality or time to recurrence. 
 Finally, our cut point optimization technique is an informative method for determining 
whether an association exists between marker expression and patient outcomes.  However, 
finding an association using the statistically-optimal cut point based on best model fit does not 
automatically mean that one has found the best cut point for clinical purposes.  The patients most 
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likely to benefit from introducing EMT markers into clinical practice are those diagnosed with 
local disease according to lymph-node evaluation and radiologic imaging, but whose EMT 
marker measurements suggest poor prognosis.  These patients generally would not receive 
chemotherapy based on conventional staging (15), but their stage and treatments might be 
reconsidered in light of their EMT marker status. 
 For example, consider how the cross-tabulation of E-cadherin status and stage changes as 
the cut point varies (Table 7).  Of 99 subjects with E-cadherin measurements and diagnosed with 
local disease, 16 were E-cadherin-negative at a cut point of 0.60 versus 6 such subjects at the 
statistically-optimal cut point of about 0.52.  The hazard ratio point estimate for a cut point of 
0.60 is nearly as strong as the point estimate for the best-fitting cut point.  Primary tumors with 
E-cadherin values between 0.52 and 0.60 probably are not biologically much different with 
respect to cancer cell detachment from tumors with values below 0.52.  Nevertheless, a notable 
number of subjects diagnosed with local disease had E-cadherin values just above the 
statistically-optimal cut point and would not have their treatments changed if the clinical cut 
point were set at the statistically-optimal value.  In addition, the cross-tabulation of stage and E-
cadherin status fits what is known about disease recurrence better at a cut point of 0.60 than 0.52, 
as about 25% of diagnosed Stage I/II CRC patients experience recurrence after surgery (4).  
Altogether, these considerations suggest that cut point model fit should be one of several criteria 
used to determine a clinical cut point, but not the sole criterion. 
 In sum, we believe that our methods for marker expression measurement, cut point 
identification, and covariate selection provide informative results and hope that future studies of 
EMT markers and patient outcomes will adopt them.  By doing so, investigators would make 
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possible meaningful comparisons of results from different research groups and valid meta-
analyses. 
 Our results suggest that E-cadherin could be a useful marker to identify colorectal cancer 
patients at risk for metastatic disease, even among those who appear to have local disease 
according to lymph-node evaluation and radiologic imaging.  Clinical measurement of E-
cadherin expression in primary tumor cancer cells might increase the accuracy of stage 
diagnosis, thereby altering the treatments that some patients receive and improving their 
outcomes. 
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Table 3. Subject characteristics for overall North Carolina CanCORS and subset in whose 
primary tumors EMT markers were measured 
Characteristic 
Mean (SD) or N (%)a 
Overall NC-CanCORS 
(N=990) 
EMT Study Sample 
(N=190) 
P-value 
Age at Baseline (years) 66.3 13.2 66.6 13.1 0.8 
Sex     0.6 
     Male 488 49.3% 90 47.4%  
     Female 502 50.7% 100 52.6%  
Race     0.6 
     Non-Hispanic White 762 77.0% 150 78.9%  
     Other 228 23.0% 40 21.1%  
Tumor Stage     0.9 
     Local 437 51.1% 100 52.6%  
     Regional 311 36.4% 66 34.7%  
     Distant 107 12.5% 24 12.6%  
     Missing/Noninformative 135  0   
Tumor Location     0.07 
     Proximal 279 42.9% 82 50.9%  
     Distal 371 57.1% 79 49.1%  
     Missing/Noninformative 340  29   
Tumor Grade     0.4 
     Well/Moderately Differentiated 539 83.7% 129 81.1%  
     Poorly/Not Differentiated 105 16.3% 30 18.9%  
     Missing/Noninformative 346  31   
Neoadjuvant Chemotherapy     0.3 
     Yes 46 8.5% 8 5.7%  
     No 496 91.5% 132 94.3%  
     Missing/Noninformative 448  50   
Neoadjuvant Radiation     0.09 
     Yes 41 7.6% 5 3.6%  
     No 501 92.4% 135 96.4%  
     Missing/Noninformative 448  50   
Died Within 5 Years of Baseline 366 37.0% 62 32.6% 0.3 
aPercentages are for informative non-missing data. 
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Table 4. Average continuous EMT marker expression in tumor tissue compared to normal 
adjacent tissue 
Marker Algorithm Scale Tissue 
Type 
N Marker Expression 
Weighted Averagea Worst Coreb 
Mean SD P-value Mean SD P-value 
E-
cadherin 
Membrane+ 
Cytoplasm 
Average 
Intensity 
Tumor 188 0.84 0.22 <0.0001 0.74 0.24 <0.0001 
  (0-3) Normal 181 0.98 0.22  0.87 0.28  
Integrin 
Beta-6 
Membrane Percent 
Positive Cells 
Tumor 181 58.1 26.8 <0.0001 69.9 25.4 <0.0001 
  (0-100) Normal 177 38.5 25.6  52.1 29.2  
Snail First Nuclearc Percent 
Positive 
Nuclei 
Tumor 185 41.7 22.1 0.02 52.3 24.9 0.0004 
  (0-100) Normal 173 47.9 27.9  62.1 27.2  
Snail Second 
Nuclearc 
Percent 
Positive 
Nuclei 
Tumor 185 44.4 26.5 0.08 57.0 29.5 0.02 
  (0-100) Normal 173 49.5 27.7  64.1 28.0  
Snail Whole Cellc Percent 
Positive Cells 
Tumor 185 34.3 24.0 0.005 46.6 28.7 0.004 
  (0-100) Normal 173 41.9 26.4  55.3 28.3  
aMarker expression values assigned as weighted average of cores by tissue type (weighted by area 
analyzed for E-cadherin, number of cells for Integrin, and number of nuclei/cells for Snail). 
bMarker expression values assigned as expression by tissue type of the core with lowest expression for E-
cadherin and highest expression for Integrin and Snail. 
cSeveral different Snail scoring algorithms were developed and applied to all tissue microarrays.  See 
Section 4.2.3 (pp. 62-64) for details. 
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Table 5. Optimally-dichotomized marker expression status cross-tabulated with tumor stage and 
with risk of dying within 5 years of surgerya,b 
 E-cadherin Integrin beta-6 Snail 
 Weighted 
Average 
Worst 
Core 
Weighted 
Average 
Worst 
Core 
Weighted 
Average 
Worst 
Core 
Stage Neg. Pos. Neg. Pos. Neg. Pos. Neg. Pos. Neg. Pos. Neg. Pos. 
Local 6 93 3 96 10 82 5 87 29 69 54 44 
Regional 5 61 3 63 3 63 1 65 14 51 45 20 
Distant 0 23 0 23 1 22 0 23 1 21 13 9 
             
Mortality Risk             
Died within 5 
   Years 
7 55 3 59 6 55 0 61 17 44 43 18 
Total 11 177 6 182 14 167 6 175 44 141 112 73 
5-Year Risk of 
   Death Post- 
   Surgery (%) 
 
64 
 
31 
 
50 
 
32 
 
43 
 
33 
 
0 
 
35 
 
39 
 
31 
 
38 
 
25 
aOf 190 overall subjects in the EMT study, the number with tumor tissue marker data available 
was 188 for E-cadherin, 181 for Integrin, and 185 for Snail. 
bMarker-negative status is expression in tumor tissue below the statistically-optimal cut point 
(low expression) and marker-positive status is expression in tumor tissue at or above the 
statistically-optimal cut point (high expression).  The a priori hypotheses were that E-cadherin-
negative subjects would have worse outcomes while Integrin-positive and Snail-positive subjects 
would have worse outcomes. 
Neg.=marker-negative status, Pos.=marker-positive status 
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Table 6. Unadjusted and adjusted Cox proportional hazards models of the effect of optimally-
dichotomized marker expression status on time-to-death censored at 5 years after surgery 
(n=190)a 
Variable Weighted Averageb Worst Corec 
Unadjusted Adjustedd Unadjusted Adjustedd 
HR 95% CI HR 95% CI HR 95% CI HR 95% CI 
E-cadherine 2.84 1.29, 6.28 2.57 1.10, 6.03 1.53 0.47, 4.95 1.56 0.32, 7.63 
         
Integrin beta-6f 0.68 0.29, 1.59 0.45 0.19, 1.08 --g -- --g -- 
         
Snailf 0.83 0.48, 1.45 0.61 0.33, 1.13 0.62 0.36, 1.08 0.57 0.32, 1.02 
aPrior to dichotomization, continuous E-cadherin measured as core average intensity (0-3) and continuous 
Integrin beta-6 and Snail measured as core percent positive cells (Integrin) or nuclei (Snail) (0-100).  
Subjects with missing data for a given marker expression variable had values imputed to retain full 
sample size.  For the value of the statistically-optimal cut point for each marker expression variable, see 
Materials and Methods section. 
bMarker expression values assigned as weighted average of tumor cores (weighted by area analyzed for 
E-cadherin, number of cells for Integrin, and number of nuclei for Snail). 
cMarker expression values assigned as average intensity of the subject’s tumor core with the lowest 
average intensity for E-cadherin, or as percent positive cells/nuclei of the subject’s tumor core with the 
highest percent positive cells/nuclei for Integrin or Snail. 
dAdjusted for age (continuous), TNM stage (local/regional/distant), neoadjuvant chemotherapy (yes/no), 
and neoadjuvant radiation therapy (yes/no).  Expression status for a given marker was not adjusted for the 
other markers. 
eComparison is E-cadherin-negative (low expression) to E-cadherin-positive (high expression). 
fComparison is marker-positive (high expression) to marker-negative (low expression). 
gNot estimable due to no deaths within 5 years of surgery among those classified as Integrin-negative. 
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Table 7. Trade-offs between strength of cut-point/time-to-death association and number of 
patients whose treatments would be reassigned, by stage distribution and 5-year risk of death for 
E-cadherin weighted average statusa 
 Cut Point 0.52c Cut Point 0.60 Cut Point 0.85 
 HR 95% CI HR 95% CI HR 95% CI 
Cox Model Estimateb 2.57 1.10, 6.03 2.40 1.29, 4.49 1.75 0.99, 3.08 
 
Stage 
E-cad 
Negative 
E-cad 
Positive 
E-cad 
Negative 
E-cad 
Positive 
E-cad 
Negative 
E-cad 
Positive 
Local (n=99) 6 93 16 83 56 43 
Regional (n=66) 5 61 11 55 41 25 
Distant (n=23) 0 23 1 22 11 12 
       
Mortality Risk       
Died Within 5  
   Years (n=62) 
7 55 14 48 42 20 
Total (n=188) 11 177 28 160 108 80 
5-Year Risk of Death 
   Post-Surgery (%) 
63.6 31.1 50.0 30.0 38.9 25.0 
       
Mortality Risk  
Effect Estimatesd 
 
Estimate 
 
95% CI 
 
Estimate 
 
95% CI 
 
Estimate 
 
95% CI 
Risk Difference (%) 32.6 3.3, 61.8 20.0 0.2, 39.8 13.9 0.7, 27.1 
Risk Ratio 2.05 1.25, 3.37 1.67 1.07, 2.59 1.56 0.99, 2.43 
aContinuous E-cadherin measured as weighted average (weighted by area analyzed) of tumor core 
average intensities (0-3) prior to dichotomization.  Of 190 subjects, 2 had missing data for E-cadherin, but 
multiple imputation enabled retention of these 2 in Cox models. 
bFor effect of dichotomous E-cadherin expression (negative versus positive) on time-to-death, adjusted 
for age (continuous), TNM stage (local/regional/distant), neoadjuvant chemotherapy (yes/no), and 
neoadjuvant radiation treatments (yes/no). 
cStatistically-optimal cut point by best model fit. 
dUnadjusted comparisons of marker-negative versus marker-positive expression status. 
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Figure 11. Kaplan-Meier survival stratified by levels of dichotomous E-cadherin weighted 
average expression status 
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Figure 12. Kaplan-Meier survival stratified by levels of dichotomous E-cadherin worst core 
expression status 
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Figure 13. Kaplan-Meier survival stratified by levels of dichotomous Integrin beta-6 weighted 
average expression status 
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Figure 14. Kaplan-Meier survival stratified by levels of dichotomous Integrin beta-6 worst core 
expression status 
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Figure 15. Kaplan-Meier survival stratified by levels of dichotomous Snail weighted average 
expression status 
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Figure 16. Kaplan-Meier survival stratified by levels of dichotomous Snail worst core expression 
status 
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Figure 17. Kaplan-Meier survival jointly stratified by levels of dichotomous E-cadherin weighted 
average expression status and dichotomous Integrin beta-6 weighted average expression status 
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Figure 18. Kaplan-Meier survival jointly stratified by levels of dichotomous E-cadherin worst 
core expression status and dichotomous Integrin beta-6 worst core expression status 
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Figure 19. Kaplan-Meier survival jointly stratified by levels of dichotomous E-cadherin weighted 
average expression status and dichotomous Snail weighted average expression status 
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Figure 20. Kaplan-Meier survival jointly stratified by levels of dichotomous E-cadherin worst 
core expression status and dichotomous Snail worst core expression status 
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Figure 21. Kaplan-Meier survival jointly stratified by levels of dichotomous Integrin beta-6 
weighted average expression status and dichotomous Snail weighted average expression status 
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Figure 22. Kaplan-Meier survival jointly stratified by levels of dichotomous Integrin beta-6 
worst core expression status and dichotomous Snail worst core expression status 
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CHAPTER 5. ESTIMATING SENSITIVITY AND SPECIFICITY OF MARKERS OF 
EPITHELIAL-MESENCHYMAL TRANSITION TO EVALUATE CANCER CELL 
DETACHMENT FROM PRIMARY TUMORS: A LATENT CLASS ANALYSIS 
 
5.1. Introduction 
 Metastases are responsible for about 90% of cancer deaths (1).  An essential component 
of cancer diagnosis is accurately assessing whether cancer cells have detached from the primary 
tumor because this impacts adjuvant therapy decisions. 
 Currently, physicians use two diagnostic tests to assess cancer cell detachment: 
examination of lymph nodes near the primary tumor and radiologic imaging.  While highly 
useful, these methods do not always successfully detect metastases.  For example, roughly 25% 
of colorectal cancer patients diagnosed with local disease later experience recurrence (4).  Most 
of these recurrences are likely due to metastases that were present at the time of diagnosis but 
were too small to be detected by imaging or lymph node evaluation.  Adding a third test could 
substantially reduce the number of joint false negative results across the entire panel of tests. 
 Markers of epithelial-mesenchymal transition (EMT), a mechanism of metastasis, might 
be able to serve this role (5).  Roughly 80% of cancer is epithelial (1) and EMT involves 
epithelial cells temporarily transforming into mesenchymal cells by decreasing expression of 
epithelial markers and increasing expression of mesenchymal markers (2, 14).  EMT marker 
expression levels measured in primary tumor cancer cells could suggest whether the tumor 
contains a substantial number of cells capable of breaking off from the tumor, thereby putting the 
patient at risk for metastatic disease (5). 
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 Previous studies have shown that EMT marker levels in primary tumor cancer cells are 
associated with patient outcomes (5, 24, 29, 43, 56, 68).  These studies did not, however, 
evaluate the diagnostic accuracy of EMT markers in terms of sensitivity and specificity, which is 
important to decide whether to add them to the panel of tests of cancer cell detachment. 
 Standard calculations of sensitivity and specificity require comparing the new test to a 
gold standard (58).  However, this condition cannot be reasonably met for EMT markers because 
imaging and lymph node evaluation are unsuccessful too often to qualify as gold standard 
measures of metastatic disease.  Latent class models provide a way to estimate sensitivity and 
specificity of each item in a panel of diagnostic tests without assuming that any of the tests is a 
gold standard (61).  In this analysis, we used latent class models to estimate the sensitivity and 
specificity of EMT markers to assess cancer cell detachment from primary tumors in a cohort of 
colorectal cancer patients. 
 5.2. Methods 
 5.2.1. Study population 
 
 Subjects were 188 cancer patients enrolled in the Cancer Care Outcomes Research and 
Surveillance Consortium (CanCORS) for whom the EMT marker E-cadherin was measured in 
primary tumor specimens (76).  CanCORS was a population-based, case-only, multi-site 
prospective cohort study of lung and colorectal cancer that enrolled subjects during 2003-06 
(48).  All subjects in this analysis were colorectal cancer patients from North Carolina.  Survey 
and medical records data were collected. 
 5.2.2. Latent class models 
 Latent variable models attempt to identify subgroups within a population by postulating 
that the subgroups represent different levels of an unobserved, error-free latent variable (62).  
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The latent variable is measured indirectly by multiple observed indicator variables (also called 
manifest variables), each of which is conceived as being generated jointly by its own random 
error term and the latent variable.  Individuals’ response patterns to the indicators can be used to 
estimate the prevalence of each latent subgroup (gamma parameter or class-membership 
probability) and, within each latent subgroup, to estimate the probability of a given response to 
each indicator (rho parameter or item-response probability).  Latent class models are latent 
variable models that use categorical indicators and postulate a categorical latent variable.  An 
important practical issue in implementing any given latent class model is deciding which 
parameters to freely estimate and which, if any, to assign a fixed, a priori value. 
 Figure 10 shows our conceptual model of the relationship between cancer cell 
detachment from the primary tumor and the tests used to assess it.  Detachment was the latent 
variable, that is, the phenomenon of interest that was not observed directly.  EMT markers, 
lymph node evaluation, and imaging were the indicators. 
 5.2.3. Diagnostic tests of cancer cell detachment from primary tumors 
 Each test was treated in models as binary test-positive versus test-negative.  Test-positive 
meant evidence supporting cancer cell detachment from the primary tumor while test-negative 
meant no evidence supporting cancer cell detachment. 
 EMT 
 EMT in primary tumor cancer cells was measured using E-cadherin (76), an epithelial 
membrane protein that plays a crucial role in adhesion between adjacent epithelial cells (1, 2).  
An epithelial cancer cell undergoing EMT will downregulate E-cadherin expression, making low 
expression suggestive of increased risk for cell detachment from the tumor (2).  E-cadherin was 
measured using immunohistochemistry in tissue microarrays.  We reported previously that, when 
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E-cadherin expression was measured as a weighted average of tumor cores among these subjects, 
low expression was associated with greater risk of death within 5 years of surgery than was high 
expression (76). 
 E-cadherin was measured on a continuous average intensity scale of 0-3.  This allowed us 
to explore the impact on EMT sensitivity and specificity of setting different cut points to define 
high expression versus low expression.  For any given cut point, EMT-positive status meant low 
E-cadherin expression (below the cut point) and EMT-negative status meant high E-cadherin 
expression (at or above the cut point).  Both EMT sensitivity and specificity were freely 
estimated in all models. 
 Lymph Node Evaluation and Radiologic Imaging 
 Each latent class model had seven parameters: one class-membership and six item-
response parameters (sensitivity and specificity for each of EMT, lymph node evaluation, and 
imaging).  Freely estimating all seven parameters would have led to poor model specification 
(see Analysis section below).  In most models, we fixed (i.e. set or restricted) two of the six item-
response parameters—either the sensitivities of lymph node evaluation and imaging or the 
specificities of lymph node evaluation and imaging—while freely estimating the other four as 
well as the class-membership parameter.  This approach required observed test results for lymph 
node evaluation and imaging for freely estimated parameters as well as determination of fixed 
values for restricted parameters. 
 Observed lymph node evaluation and imaging results were not available in CanCORS.  
As an approximation, we inferred them from subject tumor stage using the rules presented in 
Table 2.  These inferred test results were used for freely estimated lymph node evaluation and 
imaging sensitivity and specificity parameters. 
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 In models where the sensitivities of lymph node evaluation and imaging were fixed, we 
assigned a value of 60% or 80% for each fixed parameter.  Nationwide clinical data suggested 
that, between lymph node evaluation and imaging, the average sensitivity of each of these two 
tests by itself is about 65% (see Discussion for details) (4, 63).  The values of 60% and 80% 
were chosen to represent bounds to assess the influence on model results of different 
combinations of assumptions about high or low sensitivity for lymph node evaluation and 
imaging.  For models in which the specificities of lymph node evaluation and imaging were 
fixed, we assigned bounds of 90% or 100% for each fixed parameter.  These specificity bounds 
reflected our assumption that false positive results for each of these tests are rare. 
 Across models, we varied the combinations of fixed values and of which lymph node 
evaluation and imaging parameters were restricted to observe how doing so impacted the EMT 
estimates.  For each EMT cut point, we also ran a model in which all seven parameters were 
freely estimated. 
 Whether freely estimated or restricted, every lymph node evaluation or imaging 
parameter represented a binary test.  For interpretation, lymph node-positive meant that cancer 
cells were found in lymph nodes near the primary tumor and lymph node-negative that no cancer 
cells were found there.  Imaging-positive meant detection of a metastasis via imaging and 
imaging-negative indicated no such detection of metastasis via imaging. 
5.2.4. Analysis 
 Every model included all three tests and estimated a 2-class solution distinguishing high 
risk from low risk for metastatic disease.  Making parameter estimates interpretable as sensitivity 
or specificity required binary tests and grouping the data into two latent classes. 
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 A properly specified latent class model has a positive number of degrees of freedom (df), 
given by df = W – P – 1, where W is the number of possible response patterns and P is the 
number of parameters estimated (62).  Three binary indicators yielded 23 = 8 possible response 
patterns.  When all class-membership and item-response parameters were freely estimated, a 2-
class model with 3 binary indicators estimated 7 parameters (1 class-membership and 6 item-
response), leaving 0 df.   
 Using fixed sensitivity or specificity values for lymph node evaluation and imaging 
reduced the number of parameters estimated in a given model, thereby giving positive degrees of 
freedom.  Fixing the values of two item-response parameters in a model yielded 2 df.  Across 
models, different combinations of fixed lymph node evaluation and imaging values were used to 
assess the impact of different assumptions about low or high accuracy of those tests on EMT 
estimates.  We also evaluated models in which all parameters were freely estimated, i.e. 0 df. 
 We have shown previously that, when E-cadherin expression is measured as a weighted 
average of tumor cores on a continuous average intensity scale of 0-3, values of 0.52, 0.60, and 
0.85 are three possibilities for selection of a clinical cut point to distinguish low-risk from high-
risk patients (76).  We ran separate models using each of these values to create the EMT 
indicator. 
 All analyses were performed using SAS 9.3 (SAS Institute, Cary, NC), with PROC LCA 
used for the latent class analyses (64).  The SAS procedure used an iterative expectation-
maximization algorithm to obtain maximum likelihood estimates for freely-estimated 
parameters. 
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5.3. Results 
 The study sample was mainly non-Hispanic whites, about evenly divided by sex, and had 
a mean age close to the national average for colorectal cancer (63) (Table 8).  Of 188 subjects, 90 
(48%) tested positive for at least one of lymph node evaluation or imaging.  This is comparable 
to the approximately 56% of colorectal cancer cases in the United States diagnosed with regional 
or distant disease (63). 
 At an EMT cut point of 0.52, the specificity of the EMT diagnostic test was over 90% 
across all variations in lymph node evaluation and imaging parameter restrictions (Table 9).  
However, the sensitivity under these conditions was never greater than 6%. 
 For an EMT cut point of 0.60, specificity was somewhat lower than at a cut point of 0.52, 
but remained greater than 80% in all variations tested (Table 10).  Sensitivity was consistently 
higher in these models than those at a cut point of 0.52, but peaked at 14%. 
 At an EMT cut point of 0.85, specificity dropped substantially from what it was at a cut 
point of 0.60, falling to about 40% across variations in parameter restrictions (Table 11).  
Sensitivity was greater at this cut point than at the others, generally around 50-60%.   
 The model at which the EMT marker could reduce the number of false local diagnoses to 
the greatest extent used a cut point of 0.85.  When lymph node evaluation and imaging 
specificity were both fixed at 90%, EMT sensitivity and specificity were estimated to be 59% 
and 44%, respectively.  Notably, though 59% is low for optimal sensitivity, the freely-estimated 
sensitivities of lymph node evaluation and imaging in this model were 97% and 26%, 
respectively. 
 For a given set of lymph node evaluation and imaging parameter restrictions, the 
estimated prevalence of the latent class at high risk for metastatic disease was very consistent 
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across EMT cut points (Tables 9-11).  The prevalence of the high risk group was low when 
lymph node evaluation and imaging sensitivities were fixed (about 16-21%) but increased 
substantially when lymph node evaluation and imaging specificities were fixed (41-53%).  For 
each EMT cut point, freely estimating all parameters (i.e. no lymph node evaluation and imaging 
parameter restrictions) produced results roughly equivalent to the worst-performing model with 
restrictions at that cut point. 
 5.4. Discussion 
 We used latent class analysis to estimate the sensitivity and specificity of EMT markers 
to evaluate cancer cell detachment from primary tumors under varying assumptions about the 
accuracy of lymph node evaluation and imaging to assess the same.  EMT outperformed the 
freely-estimated parameters of the other tests in some scenarios and EMT specificity was over 
90% in several models, while the peak sensitivity was 59%. 
 In the United States there are around 140,000 new cases of colorectal cancer annually 
(77).  Of these, about 40% (~56,000 cases) are diagnosed as having local disease and 60% 
(~84,000 cases) as having some form of metastatic disease, whether regional or distant (63).   
Among those diagnosed with local disease, roughly 25% (~14,000 cases) later experience 
recurrence and therefore likely had undetected metastases at the time of diagnosis (4).  This 
implies that about 10% of all new colorectal cancer cases each year consist of patients who have 
metastatic disease at diagnosis but who test falsely negative for both lymph node evaluation and 
imaging.  A further implication is that, of 140,000 annual incident cases, about 98,000 truly have 
metastatic disease at the time of diagnosis rather than the 84,000 currently diagnosed as such.  
Thus, among those who truly have metastatic disease, false diagnoses would account for 
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14,000/98,000=14%.  In other words, the joint false negative proportion for lymph node 
evaluation and imaging would be 14% and therefore their joint sensitivity would be 86%. 
 Since a diagnosis of local disease requires testing negative on every measure of cancer 
cell detachment, adding a third test to the panel could substantially reduce the number of these 
diagnostic failures.  If the third test has a sensitivity of 70%, and therefore a false negative 
proportion of 30%, it would cut the joint false negative proportion for the entire panel from 14% 
to 4%.  In other words, the third test would reduce the annual number of false diagnoses of local 
disease from 14,000 to a little over 4,000. 
 A necessary trade-off for this benefit is that the number of false positives would increase.  
Some patients who truly do not have metastatic disease and who test negative for both lymph 
node evaluation and imaging would test positive for EMT.  However, the clinical consequences 
of false negative and false positive diagnoses of metastatic disease must be weighed against each 
other.  False positives lead to administration of chemotherapy when it is unlikely to benefit the 
patient.  False negatives generally lead to withholding chemotherapy when the patient truly has 
metastatic disease, which could be fatal. 
 Our analysis had several important strengths.  First, we estimated EMT sensitivity and 
specificity under a variety of reasonable assumptions about the diagnostic accuracy of lymph 
node evaluation and imaging.  The empirical estimate that about 10% of all colorectal cancer 
patients jointly test falsely negative for lymph node evaluation and imaging suggests that each of 
these two tests individually has an average sensitivity of about 65%.  This is because the 
probability of testing falsely negative for lymph node evaluation and also testing falsely negative 
for imaging is, as independent events, the product of the false negative proportions of each test.   
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 To show this, assume that lymph node evaluation and imaging have the same false 
negative proportion X.  It follows that (X)(X) = 0.14 (i.e. 14%, the proportion of colorectal 
cancer patients we estimate to truly have metastatic disease at diagnosis that is not detected by 
either test), and therefore X = 0.37.  Since the sensitivity of a single test is equal to 1 – (false 
negative proportion), for each test sensitivity = 1 – 0.37 = 0.63 = 63% (58).  We used this 
conclusion to choose our values of 60% and 80% for fixed lymph node evaluation and imaging 
sensitivity parameters.  These choices set up reasonable bounds to assess the impact on estimates 
of EMT sensitivity and specificity of assuming high or low sensitivity of lymph node evaluation 
and imaging. 
 A second strength is that latent class analysis provided valid estimates of EMT sensitivity 
and specificity because it did not require the assumption that either lymph node evaluation or 
imaging constitutes a gold standard measure of cancer cell detachment from primary tumors.  
Standard calculations of sensitivity and specificity are based on a cross-tabulation between a new 
test and a gold standard.  The only tests that EMT can be compared to in this fashion are lymph 
node evaluation and imaging.  The calculation in the preceding paragraph supports the 
conclusion that neither of the conventional tests of cancer cell detachment is perfectly accurate or 
nearly so.  Therefore, standard calculations of sensitivity and specificity would not be valid.  
These quantities must be estimated using a method that does not assume that any of the tests is a 
gold standard.  Latent class analysis is precisely suited to this task (61). 
 Third, testing the impact of several different marker expression cut points to define EMT 
status allowed us to assess whether the estimates from our latent class models reflected how one 
would expect sensitivity and specificity to change as marker cut point changes.  At a cut point of 
0.52, few subjects were classified as EMT-positive, and one would expect the test to have high 
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specificity and low sensitivity.  As the cut point was raised to 0.60 and then 0.85, the proportion 
of subjects classified as EMT-positive increased, and one would expect test specificity to 
decrease and sensitivity to increase accordingly.  Our models across different cut points matched 
this pattern exactly (Tables 9-11), supporting the validity of latent class analysis as an estimation 
technique for EMT sensitivity and specificity. 
 Our analysis had several limitations.  First, our sample size was small and there was a 
slight overrepresentation of subjects diagnosed with local disease compared to the national 
average.  Second, our dataset lacked information on lymph node evaluation and imaging test 
results, leading us to infer them based on tumor stage diagnosis.  Although this was probably a 
good approximation, we cannot verify this and it is likely that our inferred test results do not 
exactly match what was observed clinically.  A third limitation was the inherently constrained 
setting of latent class estimation with three binary indicators.  Free estimation of all model 
parameters led to model saturation (i.e. 0 df), and our saturated models performed about as well 
as our worst-performing models with lymph node evaluation and imaging parameter restrictions.  
Conversely, models restricting all 4 lymph node evaluation and imaging item-response 
parameters essentially make it impossible to estimate latent classes because only EMT can vary.  
Therefore, the best compromise was to fix some, but not all, of the lymph node evaluation and 
imaging parameters in each model. 
 Future research on this topic is warranted.  Latent class analysis of EMT marker 
sensitivity and specificity should be carried out in larger datasets with information available on 
directly observed lymph node evaluation and imaging results.  In addition, Bayesian approaches 
to latent class estimation may provide more model flexibility and allow for deeper exploration of 
the latent class structure than was possible with our relatively simple models (78-80).  For 
 
 
106 
 
example, an important assumption in latent class analysis is the local independence assumption: 
within a given latent class, that the indicators are statistically independent of each other (62).  
This is likely reasonable for tests of cancer cell detachment from primary tumors because lymph 
node evaluation, imaging, and EMT would be measured at different sites (lymph nodes, distant 
sites, and primary tumor, respectively) using different technologies and evaluated by different 
personnel (radiologist and pathologist).  Bayesian analysis could allow for evaluation of this 
assumption.  In addition, Bayesian approaches could provide more informative estimates of the 
“value added” by adding a third measure to the panel of tests of cancer cell detachment.  
However, an effective Bayesian analysis would probably require a much larger sample size than 
was available in our dataset. 
 Latent class analysis provides an important strategy to obtain valid estimates of EMT 
marker sensitivity and specificity in a setting without a true gold standard.  Our results suggest 
that EMT markers could help to substantially reduce the number of cancer patients incorrectly 
diagnosed as having local disease. 
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Table 8. Subject characteristics (n=188) 
Characteristic   
   
Age (years) (Mean, SD) 67 13 
   
Sex N % 
     Male 89 47% 
     Female 99 53% 
Race   
     Non-Hispanic White 149 79% 
     Other 39 21% 
Tumor Stage   
     Local 99 53% 
     Regional 66 35% 
     Distant 23 12% 
Lymph Node Diagnostic Statusa   
     Positive 86 46% 
     Negative 102 54% 
Radiologic Imaging Diagnostic Statusa   
     Positive 23 12% 
     Negative 165 88% 
EMT Diagnostic Status, Cut Point=0.52b   
     Positive 11 6% 
     Negative 177 94% 
EMT Diagnostic Status, Cut Point=0.60b   
     Positive 28 15% 
     Negative 160 85% 
EMT Diagnostic Status, Cut Point=0.85b   
     Positive 108 57% 
     Negative 80 43% 
aInferred from tumor stage using rules given in Table 2. 
bBased on E-cadherin expression measured as a weighted average of tumor cores on a continuous 
average intensity scale of 0-3.  Low E-cadherin expression (below the cut point) is evidence of 
EMT (EMT-positive). 
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Table 9. Estimated sensitivity and specificity of EMT markers, and prevalence of high risk for metastatic 
disease, at EMT cut point of 0.52 and varying fixed values of sensitivity or specificity for other tests 
(n=188)a 
   Estimates at EMT cut point 0.52 
Fixed Lymph-Node 
Parameter 
Fixed Imaging 
Parameter 
Model 
DF 
Sensitivity Specificity Prevalence of High Risk  
for Metastatic Diseaseb 
Sensitivity  
60% 
Sensitivity  
60% 
2 0% 93% 21% 
Sensitivity  
80% 
Sensitivity  
60% 
2 0% 93% 21% 
Sensitivity  
60% 
Sensitivity  
80% 
2 0% 93% 16% 
Sensitivity  
80% 
Sensitivity  
80% 
2 0% 93% 16% 
Specificity  
90% 
Specificity  
90% 
2 6% 94% 41% 
Specificity  
100% 
Specificity  
90% 
2 6% 94% 47% 
Specificity  
90% 
Specificity  
100% 
2 5% 94% 47% 
Specificity  
100% 
Specificity  
100% 
2 6% 94% 53% 
None None 0 0% 93% 20% 
aEMT measured by immunohistochemistry as a weighted average of cancer cell E-cadherin expression in 
primary tumor cores on a continuous average intensity scale of 0-3, then dichotomized into values below 
0.52 (EMT-positive) and at or above 0.52 (EMT-negative).  Low E-cadherin expression suggests 
occurrence of EMT in cancer cells. 
bPrevalence of low-risk group for metastatic disease is (100 – prevalence of high-risk group). 
DF=degrees of freedom 
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Table 10. Estimated sensitivity and specificity of EMT markers, and prevalence of high risk for metastatic 
disease, at EMT cut point of 0.60 and varying fixed values of sensitivity or specificity for other tests 
(n=188)a 
   Estimates at EMT cut point 0.60 
Fixed Lymph-Node 
Parameter 
Fixed Imaging 
Parameter 
Model 
DF 
Sensitivity Specificity Prevalence of High Risk  
for Metastatic Diseaseb 
Sensitivity  
60% 
Sensitivity  
60% 
2 5% 82% 21% 
Sensitivity  
80% 
Sensitivity  
60% 
2 5% 82% 21% 
Sensitivity  
60% 
Sensitivity  
80% 
2 5% 83% 16% 
Sensitivity  
80% 
Sensitivity  
80% 
2 5% 83% 16% 
Specificity  
90% 
Specificity  
90% 
2 13% 84% 41% 
Specificity  
100% 
Specificity  
90% 
2 14% 84% 47% 
Specificity  
90% 
Specificity  
100% 
2 12% 83% 46% 
Specificity  
100% 
Specificity  
100% 
2 13% 84% 53% 
None None 0 5% 83% 20% 
aEMT measured by immunohistochemistry as a weighted average of cancer cell E-cadherin expression in 
primary tumor cores on a continuous average intensity scale of 0-3, then dichotomized into values below 
0.60 (EMT-positive) and at or above 0.60 (EMT-negative).  Low E-cadherin expression suggests 
occurrence of EMT in cancer cells. 
bPrevalence of low-risk group for metastatic disease is (100 – prevalence of high-risk group). 
DF=degrees of freedom 
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Table 11. Estimated sensitivity and specificity of EMT markers, and prevalence of high risk for metastatic 
disease, at EMT cut point of 0.85 and varying fixed values of sensitivity or specificity for other tests 
(n=188)a 
   Estimates at EMT cut point 0.85 
Fixed Lymph-Node 
Parameter 
Fixed Imaging 
Parameter 
Model 
DF 
Sensitivity Specificity Prevalence of High Risk  
for Metastatic Diseaseb 
Sensitivity  
60% 
Sensitivity  
60% 
2 49% 40% 21% 
Sensitivity  
80% 
Sensitivity  
60% 
2 50% 41% 21% 
Sensitivity  
60% 
Sensitivity  
80% 
2 48% 41% 16% 
Sensitivity  
80% 
Sensitivity  
80% 
2 49% 41% 16% 
Specificity  
90% 
Specificity  
90% 
2 59% 44% 41% 
Specificity  
100% 
Specificity  
90% 
2 59% 44% 47% 
Specificity  
90% 
Specificity  
100% 
2 58% 43% 47% 
Specificity  
100% 
Specificity  
100% 
2 58% 44% 53% 
None None 0 51% 41% 21% 
aEMT measured by immunohistochemistry as a weighted average of cancer cell E-cadherin expression in 
primary tumor cores on a continuous average intensity scale of 0-3, then dichotomized into values below 
0.85 (EMT-positive) and at or above 0.85 (EMT-negative).  Low E-cadherin expression suggests 
occurrence of EMT in cancer cells. 
bPrevalence of low-risk group for metastatic disease is (100 – prevalence of high-risk group). 
DF=degrees of freedom 
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CHAPTER 6. DISCUSSION 
 6.1. Summary of findings 
 
 In this study I explored the potential for EMT markers to improve CRC outcomes by 
serving as a test of cancer cell detachment from primary tumors in addition to lymph node 
evaluation and radiologic imaging.  This exploration involved three steps.  First, I reviewed the 
literature to identify the most promising EMT markers.  Second, I measured the selected markers 
in a set of CRC primary tumors from a population-based prospective cohort study and used time-
to-event analysis to estimate associations between marker expression and time from surgery to 
death.  Third, using the one marker that was associated with mortality in the second step, I used 
LCA to estimate the diagnostic accuracy of EMT while accounting for lymph node evaluation 
and imaging, but without assuming that any of the tests was a gold standard. 
 6.1.1. Associations between EMT marker expression and time-to-death 
 I decided to study the most promising marker from each of the three categories of EMT 
markers: epithelial markers, mesenchymal markers, and inducers.  Based on the literature, I 
selected E-cadherin, Integrin beta-6, and Snail, respectively.  The expression of each marker was 
measured on a continuous scale in CRC primary tumors from a population-based prospective 
cohort study.  For E-cadherin, this was average intensity ranging from 0-3.  For Integrin and 
Snail, I used the scale of percent positive cells or nuclei, respectively (range: 0-100).  In addition, 
for a given marker the expression score for each subject was assigned in two different ways: as a 
weighted average of tumor cores and as the worst tumor core, where “worst” meant lowest 
expression for E-cadherin and highest expression for Snail and Integrin.  For each of the 
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resulting six continuous marker expression variables, I examined every possible dichotomization 
of the data to identify the cut point with the best model fit in a bivariate proportional hazards 
model between dichotomous marker expression and time-to-death. 
 When marker expression was dichotomized at the continuum-specific statistically-
optimal cut point, I found for E-cadherin weighted average that, compared to high expression, 
low expression was associated with a greater hazard of dying within 5 years of surgery.  
Optimally-dichotomous expression was not associated with outcomes for any of the other marker 
expression variables, including E-cadherin worst core.  Adjusting for age, tumor stage, and 
neoadjuvant treatments did not change any of these findings. 
 To further explore how E-cadherin weighted average data might be implemented 
clinically, I compared several different cut points along this continuum that could each predict 
outcomes: the statistically-optimal cut point of about 0.52 as well as 0.60 and 0.85.  I found that, 
in moving from 0.52 to 0.85, the strength of the proportional hazards association between 
dichotomous marker expression and time-to-death attenuated but precision increased.  The same 
pattern appeared on the risk-difference and risk-ratio scales. 
 Cross-tabulating dichotomous E-cadherin weighted average expression status and tumor 
stage further complicated the picture.  The statistically-optimal cut point would lead to changes 
in treatment for only 6 of 99 subjects diagnosed with local disease and having E-cadherin 
measurements available.  The corresponding numbers for 0.60 and 0.85 were 16 and 56, 
respectively.  These results should be compared to the clinical observation that about 25% of 
CRC patients diagnosed with local disease later experience recurrence (4).  This suggests that 
about 25 of the 99 subjects diagnosed with local disease and having E-cadherin measurements 
would ideally be classified as E-cadherin-negative and therefore as EMT-positive. 
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 6.1.2. Latent class estimates of EMT sensitivity and specificity to evaluate cancer cell 
           detachment from primary tumors 
 
 I used LCA to estimate the diagnostic accuracy of EMT markers to evaluate cancer cell 
detachment from primary tumors.  Based on the finding from time-to-event analysis that only E-
cadherin weighted average was associated with outcomes, in the LCA I classified subjects as 
EMT-positive or EMT-negative based on their E-cadherin weighted average measurements.  I 
examined results when varying each of several different conditions: assumptions about the 
sensitivity or specificity of lymph node evaluation and radiologic imaging, as well as the E-
cadherin weighted average cut point used to classify subjects as EMT-positive or EMT-negative. 
 The LCA results reproduced the general patterns one would expect to see when varying 
the cut point of a continuous variable.  When the cut point was at a low value of 0.52, such that 
few subjects were classified as EMT-positive, the specificity of the marker was high (over 90%) 
but the sensitivity was low (under 10%).  As the cut point was progressively raised and the 
proportion of subjects classified as EMT-positive increased accordingly, the specificity 
decreased and sensitivity increased.  The fact that the LCA models produced results that fit the 
expected pattern of changes in sensitivity and specificity as cut point changed supported the 
validity of LCA as an estimation procedure in this setting. 
 For metastatic disease diagnosis, false negatives have more serious clinical consequences 
than false positives.  A false negative in this setting is a case that truly has metastatic disease but 
receives a negative result for every diagnostic test.  In other words, the patient would need 
chemotherapy but likely would not receive it.  A false positive would occur when the patient 
truly does not have metastatic disease but receives a positive result for at least one test.  This 
patient would not benefit much from chemotherapy but would probably receive it.  The 
consequences of a false positive would generally be that the patient would unnecessarily suffer 
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the serious side effects of chemotherapy.  In contrast, the consequences of a false negative could 
easily be fatal. 
 I estimated that there are about 14,000 cases each year in the United States of colorectal 
cancer patients with metastatic disease at the time of diagnosis who nonetheless are diagnosed 
with local disease (4, 77).  In addition, I estimated that there are about 42,000 colorectal cancer 
patients in the United States each year who are diagnosed with local disease and truly do not 
have metastatic disease (4, 63, 77).   
 The most plausible set of assumptions that I explored using LCA assumed was that, 
between lymph node evaluation and imaging, one of them has a sensitivity of 80% and the other 
a sensitivity of 60%.  Under these conditions, the best-performing EMT cut point that I 
examined—E-cadherin weighted average cut point of 0.85 on a continuous average intensity 
scale of 0-3—had an EMT sensitivity of about 50% and specificity of about 40%.  This implies 
an EMT false negative proportion of 50% and false positive proportion of 60%.   
 Combining these EMT diagnostic accuracy estimates with the population estimates for 
true and false diagnoses of local disease allows us to see the overall clinical trade-off that EMT 
markers offer per the results of my analyses.  In short, implementing EMT as a test of metastatic 
disease at an E-cadherin weighted average cut point of 0.85 could eliminate 50% of the false 
diagnoses of local disease each year (about 7,000 cases).  This gain would come at the expense 
of over-treating 60% of those who are currently accurately diagnosed with local disease (about 
25,200 cases). 
 The best-performing EMT estimates that I found involved a cut point of 0.85 and 
assumed a lymph node specificity of 90% and imaging specificity of 90%.  Under these 
conditions, EMT had a sensitivity of 59% and specificity of 44%, implying a false negative 
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proportion of 41% and false positive proportion of 56%.  These estimates translated to 
elimination of about 8,300 false diagnoses of local disease per year, but at the cost of over-
treating about 23,500 cases that are currently correctly diagnosed with local disease. 
 In sum, under the best estimates of sensitivity and specificity that I obtained, EMT 
markers presented a clinical trade-off between eliminating false negatives and creating new false 
positives that would probably not be considered a net improvement.  Under the most plausible 
assumptions, even the best-performing EMT cut point produced sensitivity and specificity 
estimates that would not represent a net improvement. 
 6.2. Strengths and limitations 
 The project had a number of important strengths.  First, it used a population-based 
sample, meaning it was based on a well-defined source population and therefore should be 
regarded as having greater external validity than would a hospital-based sample (75).  Although 
we were only able to measure EMT markers in primary tumor specimens for roughly 20% of NC 
CanCORS subjects, the EMT study sample seemed to closely resemble overall NC CanCORS, 
preserving the interpretation of the EMT study sample as population-based. 
 A second strength is that we measured continuous marker expression data using 
automated procedures.  Continuous data enabled a more detailed examination of clinically-
informative cut points and exploration of how marker expression varied with time-to-death than 
would have been possible with ordinal data, such as that typically produced by manual scoring.  
In addition, we assigned continuous expression scores in two ways: as a weighted average of 
cores by tissue type (normal or tumor) and as the “worst” core by tissue type.  This allowed us to 
assess the impact of marker expression heterogeneity throughout a tumor.  As will be discussed 
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later, this assessment of heterogeneity was severely limited by the lack of consistent, informative 
sampling of primary tumors. 
 Third, we assessed the reliability of our automated annotations of tissue specimens by 
comparing them to gold-standard manual annotations.  We found correlations of about 90% 
between the automated scores produced by automated annotation and the automated scores 
produced by manual annotation.  This quality-control step supported the accuracy of our marker 
expression measurements. 
 Fourth, we developed an automated procedure to examine, for each marker expression 
continuum, every possible cut point and its relationship with time to patient death.  In addition to 
exhaustiveness, we also identified an objective criterion that could be used to find a clinically-
informative cut point based on best model fit.  This approach allowed us to fully exploit the 
richness of the continuous data that we measured.  It also made it possible to consider the impact 
of choosing clinical cut points that differed from the statistically-optimal cut point.  For example, 
we found for E-cadherin weighted average that the statistically-optimal cut point would lead to a 
number of patients whose treatments would be reassigned that was probably too low, given the 
proportion of subjects diagnosed with local disease who later experience recurrence.  However, 
by exploring multiple cut points, we identified a cut point with a point estimate only a little 
weaker than the one at the statistically-optimal cut point, but with better precision and a more 
appropriate number of patients whose treatments would be reassigned.  In short, while the 
statistically-optimal cut point might not be the clinically-optimal cut point, our procedures 
towards data collection and analysis provided maximum flexibility to evaluate such trade-offs. 
 Finally, I estimated EMT marker sensitivity and specificity using LCA to avoid the 
assumption that any diagnostic test of metastatic disease constituted a gold standard, which was 
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likely not a valid assumption.  Diagnostic accuracy as expressed by sensitivity and specificity is 
an important measure of the clinical benefit of any biomarker.  In the setting of metastatic 
disease diagnosis, no gold standard exists to which EMT markers can be compared using 
standard calculations.  A true gold standard would have both a sensitivity and specificity of 
100%.  While lymph node evaluation and imaging could well have specificities close to 100%, I 
estimated that the average sensitivity for each of them is only around 65%.  Using LCA allowed 
me to obtain valid accuracy estimates for EMT while still taking into account the accuracy of 
lymph node evaluation and imaging. 
 The study had several limitations.  First was the small sample size.  This led to poor 
precision even among the statistically-significant estimates.  The low power of the full sample 
size also prevented me from dividing the dataset into training and validation sets.  It also 
impeded a richer consideration of different E-cadherin weighted average cut points to better 
explore which one might be best for clinical purposes.  Aside from examining a cut point of 
about 0.52 because it had the best model fit, I examined the alternative cut points of 0.60 and 
0.85 because they either remained statistically significant (0.60) or were very nearly so (0.85).  
Most cut points in the range of 0.50 to 1.05 had strong hazard ratio point estimates between 1.60 
and 2.60.  However, the lower 95% confidence limit would often dip to around 0.85 or 0.90.  
Though this was almost certainly due to the small sample size rather than a lack of effect, such 
imprecision made it difficult to consider cut points such as 0.70 or 0.90 more deeply. 
 Second, the goat antibodies that we used for Snail and Integrin beta-6 could have been 
rendered ineffective by nonspecific staining.  My analyses suggested that Snail and Integrin 
expression levels simply had no effect on patient time-to-death.  However, this could have been 
due to poor performance of the particular antibodies that were used rather than a reflection of a 
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genuine lack of association between these markers and patient outcomes.  We were not able to 
examine this possibility but it is a potentially serious flaw in these marker measurements. 
 Third, some amount of selection bias was potentially present in the sample because not 
all eligible CRC cases enrolled in NC CanCORS.  During the enrollment period, there were 
1,899 nominally-eligible and 1,506 fully-eligible incident CRC cases in the study catchment area 
(Figure 3).  Of these, 990 patients enrolled in the study.  Thus, NC CanCORS included 66% of 
fully-eligible cases and 52% of nominally-eligible cases.  Any systematic differences between 
those who did not enroll and those who did would bias our results away from the true estimates 
for the source population.  For example, 85 eligible cases could not give consent to enroll and 
had no proxy to consent for them.  These cases were probably sicker at the time of diagnosis than 
those who enrolled.  Their inability to consent means we have no study data for them, including 
tumor specimens.  Exclusion of these cases meant that NC CanCORS, and therefore the EMT 
study sample, differ at least somewhat from the targeted source population. 
 Fourth, the dataset had a large amount of missing data.  This problem arose in two 
different ways: as substantial proportions of missing data on variables that were collected, and 
also lack of variables that were relevant to the analysis.  For the first issue, variables for 
neoadjuvant treatments—which were part of our multivariate Cox modeling adjustment set—had 
missing or non-informative values for 50 of 190 subjects (26%) in the EMT study sample.  The 
time-to-event outcome variable of time from surgery until all-cause mortality was missing for 27 
of 190 subjects (14%).  Missing values for these variables had to be imputed using multiple 
imputation before running proportional hazards models.  Other variables relevant to 
characterizing cancer patients also had substantial proportions of missing or non-informative 
data, such as tumor grade (16%) and tumor location (15%).  Although multiple imputation is as 
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robust a method for handling missing data as is available, and though our effect estimates were 
stable in sensitivity analyses comparing complete cases to all cases with imputed values for 
missing data, imputation is still inferior to complete information on all subjects. 
 The problem of crucial variables not being available at all was manifest in the latent class 
analysis.  Observed test results were needed for all three tests: lymph node evaluation, radiologic 
imaging, and EMT.  Results for the first two were not part of the CanCORS medical records data 
collection.  Therefore, results for these two variables were inferred from tumor stage, which 
likely did not exactly match what was observed clinically. 
 Fifth, in the latent class analysis, tests of metastatic disease presented a highly 
constrained setting that complicated estimation of meaningful results.  The reason is that the 
flexibility of latent class models varies directly with the number of possible response patterns.  In 
a setting with three binary tests, there are only 8 possible response patterns.  Since free 
estimation of all parameter yields a poorly-performing model with 0 df, better model 
specification and performance were achieved when fixing the values of two parameters (of 7 
possible) per model.  In some models with restrictions these parameters were the sensitivities of 
lymph node evaluation and imaging; in others they were the specificities of these two tests.  
While reasonable fixed values were assigned, clearly our results are limited to the sets of 
assumptions implemented in the models that were run.  Had we used different combinations of 
fixed values, we would have observed different results. 
 The sixth and final limitation of the study was probably the most important.  EMT marker 
expression likely is not homogeneous throughout the cancer cells in a primary tumor.  Rather, 
certain portions of the tumor are probably much more likely to have cancer cells likely to 
undergo EMT compared to other parts of the tumor, with the invasive front thought to be the 
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chief source of transitioning cells (81).  Ideally, every primary tumor in the study would have 
been sampled in an informative, consistent manner, such as systematically sampling the invasive 
front, tumor center, and an edge of the tumor away from the invasive front (5).  This would have 
enabled us to estimate, say, not just the association between E-cadherin weighted average 
expression and outcomes, but between invasive front E-cadherin weighted average expression 
and outcomes.  Separately, we could also have estimated the association between tumor center E-
cadherin weighted average and outcomes.  This would have allowed us to assess marker 
expression heterogeneity most directly. 
 However, informative tumor sampling was not carried out in CanCORS.  This meant that 
we were looking at some unknown mixture of invasive front samples, tumor center samples, and 
samples from other parts of the tumors.  The most probable impact of this problem would have 
been to attenuate our effect estimates compared to what they would be if we only had invasive 
front expression.  I would expect marker expression from parts of the tumor other than the 
invasive front to have a weaker association with outcomes than what would be seen with 
invasive front expression.  A further implication is that we could not evaluate tumor expression 
heterogeneity.  This could explain why we saw no effect of E-cadherin worst core expression on 
outcomes but did see a relationship for E-cadherin weighted average expression.  “Worst core” 
may not mean much if the tumors are not sampled in an informative way.  The weighted average 
at least had the virtue of being more representative of marker expression for the overall tumor 
because it generally accounted for more cells than did the worst core. 
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 6.3. Public health implications and future directions 
 The potential clinical and public health benefit of EMT markers is as an additional 
diagnostic test of metastatic disease to complement conventional tests.  Specifically, the markers 
could identify as high risk a substantial number of patients who truly have metastatic disease at 
diagnosis but that test negative according to lymph node evaluation and imaging.  This would 
enable these patients to receive more appropriate treatments than they would otherwise. 
 I found that E-cadherin measured as a weighted average of tumor cores was associated 
with time from surgery to patient death.  However, the picture was complicated when I estimated 
the diagnostic accuracy of E-cadherin weighted average as marker sensitivity and specificity.  I 
examined a variety of combinations of E-cadherin cut point and assumptions about the 
diagnostic accuracy of lymph node evaluation and imaging.  I did not find E-cadherin accuracy 
estimates that simultaneously resulted from plausible assumptions and provided an acceptable 
trade-off between the number of false negatives that would be eliminated and the number of new 
false positives that would result. 
 These mixed results and the strengths and limitations of the study suggest important 
considerations for future work on EMT markers and patient outcomes.  First, much larger sample 
sizes are needed.  Specifically, sample sizes must be big enough that the sample can be divided 
into training and validation sets, each of which having much better precision than the sample 
used in the present study. 
 Second, informative tumor sampling is essential.  I recommend that every primary tumor 
be sampled for at least two cores from each of the invasive front, tumor center, and an edge of 
the tumor away from the invasive front.  Cores from different parts of the tumor should not be 
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averaged together.  Different analyses should be run using marker expression data from each of 
the various tumor portions separately. 
 Third, future studies should collect data on all-cause mortality, cancer-specific mortality, 
and time to recurrence.  This would enable comparison between different time-to-event analyses 
using each of the three outcomes to assess whether this makes a difference.  In our study, we 
only had all-cause mortality available and therefore could not compare the results to what would 
have been obtained with cancer-specific mortality or time to recurrence as the outcome. 
 Fourth, future latent class estimates of EMT marker sensitivity and specificity should be 
based on direct observations of lymph node evaluation and imaging test results, not inferred from 
tumor stage or other information. 
 Finally, latent class analyses to estimate EMT marker diagnostic accuracy should be 
carried out within a Bayesian framework.  This would allow for more informative estimates and 
greater flexibility in testing assumptions than was possible with our simple frequentist models.  
An effective Bayesian analysis would almost certainly require a substantially greater sample size 
than was available in the present work. 
 In this study we have developed numerous ideas about how best to measure EMT 
markers in primary tumors and analyze the data to provide clinically-informative estimates.  In 
turn, these estimates can be used to decide whether and how to use the markers in clinic.  Though 
we lacked the resources to implement all of our ideas, we hope that future studies will be able to 
do so and thereby realize our intention in undertaking this work to improve cancer outcomes. 
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APPENDIX A. SEARCH TERMS FOR SYSTEMATIC LITERATURE REVIEW OF 
EMT MARKERS AND OUTCOMES 
 Below is the search we ran in PubMed.  Search terms were reformatted and run in 
EMBASE via Elsevier and BIOSIS via Thomson Reuters Web of Science. 
(epithelial mesenchymal[tw] OR epithelial to mesenchymal[tw] OR emt[tw] OR epithelium 
mesenchyme[tw]) AND (tumor markers, biological[mesh] OR tumor marker*[tw] OR twist*[tw] 
OR e-cadherin[tw] OR ecadherin[tw] OR n-cadherin[tw] OR ncadherin[tw] OR vimentin*[tw] OR 
fibronectin*[tw] OR zeb1[tw] OR zeb 1[tw] OR zeb2[tw] OR zeb 2[tw] OR Cytokeratin*[tw] OR 
snail[tw] OR slug[tw] OR beta catenin[tw] OR integrin*[tw] OR microRNA*[tw] OR micro 
RNA*[tw] OR miRNA*[tw] OR TGF-beta*[tw] OR TGFbeta*[tw] OR TGFB*[tw] OR transforming 
growth factor beta*[tw]) AND (mortality[mesh] OR mortality[subheading] OR mortalit*[tw] OR 
prognosis[mesh] OR prognosis[tw] OR prognost*[tw] OR surviv*[tw] OR hazard[tw] OR rate[tw] 
OR risk[tw] OR ratio[tw] OR analys*[tw] OR analyz*[tw]) AND ("Colorectal Neoplasms"[Mesh] 
OR (tumor[tw] OR tumors[tw] OR tumour*[tw] OR cancer[tw] OR cancers[tw] OR carcinoma*[tw] 
OR adenoma*[tw] OR adenocarcinoma*[tw] OR polyp[tw] OR polyps[tw]) AND (colorectal[tw] 
OR colonic[tw] OR rectal[tw] OR colon[tw] OR rectum[tw] OR anal[tw] OR anus[tw] OR large 
bowel[tw])) 
  
 The search consisted of four groups of terms: EMT, tumor markers, outcomes, and 
colorectal cancer.  To be included, an item had to contain at least one term from each of the 
groups.  The tumor-marker group was designed to capture any marker using the generalized 
“tumor markers, biological” MeSH term and “tumor marker*” text-word term.  Particular 
markers were specified as a “safety net” for markers prominent in the EMT literature but did not 
exclude other markers.  The search can be modified from colorectal cancer to other kinds of 
cancer by replacing the colon- and rectum-specific terms in the last group with analogous terms 
for other tumor sites. 
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APPENDIX B. MARKER CUT POINT OPTIMIZATION MACRO: SAS CODE  
AND DETAILS 
 
 B.1. Introduction 
 At the end of this supplement we present the SAS code for the macro (“opt”) used to find 
the cut point for a continuous marker expression variable that yields the best model fit for a Cox 
regression of the association between the dichotomized marker expression variable and time 
from surgery to patient death. 
 For anyone who wishes to use the macro, we describe the features of the code that can be 
adapted to the investigator’s data and desire to control the output.  For ease of reference, every 
fifth line of code has been numbered.  Skipped lines and annotations do not count in the line 
numberings.  The code was written using SAS version 9.3 (SAS Institute, Cary, NC). 
 B.2. Features of the code 
 The macro input is a dataset with one observation per subject and containing the 
following information: continuous marker expression variables, length of time from surgery to 
patient death, and any censoring variable to be used in Cox proportional hazards modeling.  In 
our example, the input dataset is called “markercore7” and is read-in in line 3. 
 For any continuous marker expression variable, the macro orders the expression values of 
all subjects from least to greatest, identifying the observed range of values.  For a given marker 
expression value, the program dichotomizes the variable at that value, thereby establishing 
distinct marker-positive and marker-negative groups as defined by the particular cut point. 
 The dichotomized marker expression variable is fit as the only independent variable in a 
Cox proportional hazards model of time from surgery to death (PROC PHREG in lines 41-45).  
In our example, TTE5 is the time-to-event variable, with administrative censoring at 5 years.  
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CENSOR5 is an indicator of whether the subject was censored at 5 years (0=not censored, 
1=censored).  The Cox model produces a fit statistic for the current iteration of the program. 
 The macro repeats this process for every continuous expression value in the observed 
data.  The dichotomous marker expression variable is named “cut.”  The macro output is a list of 
expression values and corresponding model fit statistics when marker expression is dichotomized 
at that particular expression value.  The list is ordered from lowest fit statistic (best fit) to highest 
fit statistic (worst fit).  See Section 3 below for an example. 
 Investigators using the macro may wish to tailor the output at several points.  First, the 
investigator can control what kind of model fit statistics are produced by setting the value of 
“_n_” in line 49.  Setting the value to 1 requests -2 log likelihood statistics, a value of 2 requests 
AIC statistics, and 3 requests BIC statistics.  We chose to work with BIC statistics and so used a 
value of 3, as well as naming the fit statistic output variable “bic.” 
 Second, the macro incorporates a “switch” variable that can be set to 0 or 1.  Setting 
switch=0 produces a complete list of all expression values and corresponding model fit statistics, 
ordered from lowest to highest fit statistics.  Switch=1 restricts the output to the lowest model fit 
statistic and its corresponding expression value. 
 The final line of the code calls the macro for a particular continuous marker expression 
variable: “%opt(EAIWAV_T,0);” (line 85).  The items in parentheses are particular values of the 
general form (continuous marker expression variable, switch variable).  Our example expression 
variable is EAIWAV_T, which stands for “continuous E-cadherin expression measured on the 
average intensity scale, values assigned as weighted averages of cores, for tumor cores.”  We 
request that the program show the full macro output for this variable and so have set switch=0. 
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B.3. Sample macro output 
 Below is the first 10 rows of output for marker expression variable EAIWAV_T with 
BIC model fit statistics.  Since we had 190 subjects in our dataset, the actual list of output results 
has as many rows as the number of subjects, minus ties for continuous expression values.  These 
first 10 results are the 10 lowest (best-fitting) BIC values for this expression continuum in our 
study.  E-cadherin was measured on a continuous average intensity scale ranging from 0 to 3. 
Result for EAIWAV_T 
 
cut bic 
0.51537 624.441 
0.56128 624.976 
0.50443 625.234 
0.47189 625.410 
0.52104 625.965 
0.56590 626.022 
0.47018 626.048 
0.58048 626.208 
0.82207 626.332 
1.55779 626.346 
 
 The top result sets the cut point at an expression value of 0.51537 (what we refer to in the 
main text as “about 0.52”) and has the best fit of all bivariate associations between dichotomous 
marker expression status and time-to-death in our observed data.  We thus refer to 0.51537 as the 
statistically-optimal cut point for E-cadherin weighted average.  A dichotomous 
positive/negative status variable was created for E-cadherin weighted average using this cut 
point.  We used this dichotomous variable in the E-cadherin weighted average Cox models 
presented in Tables 5 and 6. 
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 B.4. Comparison of optimization macro to receiver operating characteristic (ROC)  
         curves 
 
 Our approach is an alternative to ROC curves.  Both methods can be used to select a cut 
point along a continuum of marker expression values based on a criterion that relates marker 
expression to patient outcomes.  The methods differ in two important respects.  
 First, the form of subject outcomes is different.  ROC curves use a binary outcome of 
whether a subject died (yes/no) while our approach uses continuous time-to-death.  It matters 
whether a patient died 5 months or 50 months after surgery.  ROC curves do not account for such 
distinctions whereas our approach does.   
 Second, the criterion used to identify a cut point differs between the methods.  In ROC 
curves, the cut point selected is typically the one corresponding to the most upper-left-hand point 
on a plot of sensitivity versus (1 – specificity) (i.e. true positive rate versus false positive rate).  
In our approach, the statistically-optimal cut point is the one yielding the best model fit in a 
bivariate proportional hazards model of dichotomous marker expression and continuous time-to-
death. 
 This difference between cut point selection criteria implies a difference in interpretation 
between the two methods.  Being based on measures of sensitivity and specificity, the cut point 
selected by an ROC curve is usually interpreted as the one that should be implemented clinically.  
However, selecting the upper-left-hand corner of the ROC curve implies that false positives and 
false negatives have clinical consequences of roughly equal importance, which is rarely true.  In 
contrast, the optimal cut point in our approach is a statistical measure of the largest difference in 
the observed data between hazard functions for marker-positive and marker-negative subjects.  
Thus, the direct application of our method is to determine whether an association exists between 
marker expression and time-to-death.  The statistically-optimal cut point might or might not be 
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judged to be best for clinical use, but that determination requires consideration of additional 
information besides model fit alone. 
 B.5. SAS code for marker cut point optimization macro 
%macro opt(var,switch); 
/* no missing */ 
  data _internal_; 
    set markercore7; 
    if &var^=.; 
  run;                                                        /* line 5 */ 
/* values of &VAR ordered */ 
  proc freq data=_internal_ noprint; 
    tables &var/out=_table_(keep=&var); 
  run; 
/* number unique values of &VAR to &NN */ 
  data _null_; 
    set _table_ end=end;                                      /* line 10 */ 
    if end then do; 
      nn=put(_n_,8.); 
   call symput("nn",nn); 
    end; 
  run;                                                        /* line 15 */ 
/* initialize the output data set to _NULL_ */ 
  data _rsq_; 
    set _null_; 
  run; 
  %do i=1 %to &nn; 
/* get the present cut point */ 
    data _cut_;                                               /* line 20 */ 
   set _table_; 
   rename &var=cut; 
   if _n_=&i then do; 
     xx=put(&var,25.10); 
  call symput("cut",xx);                            /* line 25 */ 
  output; 
   end; 
 run; 
/* merge and assign to groups */ 
 data _use_; 
   if _n_=1 then set _cut_;                              /* line 30 */ 
   set _internal_; 
   group=(&var<=cut); 
   x1=group*&var; 
   x0=(1-group)*&var; 
 run;                                                    /* line 35 */ 
 proc datasets; 
   delete _cut_; 
 run; 
 quit; 
/* model */ 
 ods listing close;                                      /* line 40 */ 
 proc phreg data=_use_; 
   model TTE5*CENSOR5(1)=x1; 
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   ods output fitstatistics=_fit_(keep=withcovariates); 
 run; 
 quit;                                                   /* line 45 */ 
 ods listing; 
    data _fit_; 
      set _fit_; 
      if _n_=3; 
      rename withcovariates=rsquare;                          /* line 50 */ 
    run; 
 data _rsq_; 
   set _rsq_ _fit_(in=in); 
   keep cut bic; 
   if in then do;                                        /* line 55 */ 
     cut=&cut; 
  bic=rsquare; 
   end; 
 run; 
 proc datasets;                                          /* line 60 */ 
   delete _use_ _fit_; 
 run; 
 quit; 
  %end; 
  proc datasets;                                              /* line 65 */ 
    delete _table_ _internal_; 
  run; 
  quit; 
  proc sort data=_rsq_ out=_rsq_; 
    by bic;                                                   /* line 70 */ 
  run; 
  title "Result for %upcase(&var)"; 
  proc print noobs data=_rsq_ 
  %if &switch=1 %then %do; 
    (obs=1)                                                   /* line 75 */ 
  %end; 
  ; 
  run; 
  title; 
  proc datasets;                                              /* line 80 */ 
    delete _rsq_; 
  run; 
  quit; 
%mend; 
 
/* call macro for each continuous expression variable */ 
 
%opt(EAIWAV_T,0);                                             /* line 85 */ 
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APPENDIX C. LATENT CLASS ANALYSIS: SAS CODE AND DETAILS 
 Below is sample code for one of the latent class models that I ran.  Running a model with 
parameter restrictions using PROC LCA in SAS 9.3 required three steps.   
 First, I created a dataset with starting values for each parameter (lca_start_85_2).  Since I 
modeled 2-class solutions for three binary indicators—EMT, lymph node evaluation, and 
radiologic imaging—each model had seven parameters: 1 gamma (class-membership 
probability) and 6 rho (item-response probabilities, specifically sensitivity and specificity for 
each of the three indicators).  In the example, I used EMT status defined as E-cadherin weighted 
average expression dichotomized at a cut point of 0.85 on a continuous average intensity scale of 
0-3 (EMT85).  The gamma parameter was set to “random” start values of 0.5 for each of the two 
classes.  Class 1 was the “healthy” class, that is, those who tested negative for a given indicator 
and corresponded to those at low risk for metastatic disease.  Therefore, it was the group in 
whom we obtained estimates for specificity.  Class 2 was the “sick” class, that is, those who 
tested positive for a given indicator and corresponded to those at high risk for metastatic disease.  
Sensitivity was estimated among Class 2. 
 The second step was to create a dataset that designated which parameters would be 
restricted (i.e. given fixed values and not estimated) and which would be freely estimated 
(lca_restr_85_2).  In the example, the fixed parameters were lymph node (LN3) sensitivity of 0.8 
and radiologic imaging (RI) sensitivity of 0.6.  The rest were freely estimated.  Fixed parameters 
were designated with a 0 and freely estimated parameters with a 1.  However, PROC LCA 
required that restricted parameters be designated with a 0 in only one of the two classes.  
Therefore, each fixed parameter is given a value of 0 for one of the two classes and a value of 1 
for the other class. 
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 The third step is to run the analysis using PROC LCA and incorporating the start-value 
and restriction datasets set up in the first two steps.  The RHO PRIOR statement is used to ensure 
smooth model estimation in the event that any of the estimates would have values of 0 or 1, 
making it difficult for the algorithm to compute an overall solution and appropriate standard 
errors. 
/* set up parameter start values */ 
 
DATA lca_start_85_2; 
INPUT param $ group variable $ respcat estlc1 estlc2; 
DATALINES; 
 GAMMA 1 . . 0.5 0.5 
 BETA  1 . . 0.0 0.0 
 RHO  1 LN3 1 0.6 0.2 
 RHO  1 RI 1 0.6 0.4 
 RHO  1 EMT85 1 0.7 0.3 
 RHO  2 LN3 2 0.4 0.8 
 RHO  2 RI 2 0.4   0.6 
 RHO  2 EMT85 2 0.3 0.7 
 ; 
RUN; 
 
 
/* assign parameters as restricted or freely estimated */ 
 
DATA lca_restr_85_2; 
INPUT param $ group variable $ respcat estlc1 estlc2; 
DATALINES; 
 GAMMA 1 . . 1 1 
 BETA  1 . . 1 1 
 RHO  1 LN3 1 1 0 
 RHO  1 RI 1 1 0 
 RHO  1 EMT85 1 1 1 
 RHO  2 LN3 2 1 1 
 RHO  2 RI 2 1 1 
 RHO  2 EMT85 2 1 1 
 ; 
RUN; 
 
/* run latent class model using designated start values and restrictions */ 
 
PROC LCA data=lca OUTEST=lca_out_85_2 START=lca_start_85_2 
RESTRICT=lca_restr_85_2; 
 TITLE1 "EMT85 Model 2: LN fixed Se 0.80, RI fixed Se 0.60"; 
 NCLASS 2; 
 ITEMS LN3 RI EMT85; 
 CATEGORIES 2 2 2; 
 MAXITER 5000; 
 CRITERION 0.000001; 
 RHO PRIOR=1; 
RUN;  
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